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o
Nucleolar structure evaluation and manipulation
Field of the invention
The present invention relates to means and methods for evaluating and/or manipulating nucleolar
morphology.
Background to the invention
Within the nucleus, the nucleolus is a specialized functional domain essential to gene expression (1). It is
the site where the initial steps of ribosome biogenesis take place (2). Ribosomes are ribonucleoprotein
(RNP) nanomachines converting the genetic information encoded in mRNAs into proteins. The human
ribosome contains four ribosomal RNA (rRNAs) and eighty r-proteins organized in two subunits, each
performing specialized functions in translation (3, 4). The small subunit (SSU), which consists of a single
rRNA (18S) and thirty-three r-proteins, decodes the mRNA, while the large subunit (LSU), comprising
three rRNAs (5S, 5.8S, and 28S) and forty-seven r-proteins, bears the peptidyl transferase center where
amino acids are joined together into proteins. In the nucleolus, the 18S, 5.8S, and 28S rRNAs are
synthesized by RNA polymerase I (Pol I) as long precursors, pre-rRNAs are modified, folded, and
processed, and most r-proteins are assembled to form ribosomal subunits (2).
r-proteins are not involved in ribosome-mediated catalysis of peptide bond formation (3,5). Nonetheless,
r-proteins play essential roles in shaping and maintaining the overall structure of the ribosomal subunits,
and mutations in r-proteins are frequently associated with developmental disorders and human diseases
(6). Notably, ribosomopathies are cancer predisposition syndromes caused by ribosome biogenesis
dysfunction (7), due to mutations in r-proteins or ribosomal assembly factors r-proteins are intimately
linked to tumorigenesis, being directly involved in regulating the steady-state level of the anti-tumor
protein p53 (8). This occurs via activation of specific anti-tumor surveillance pathways, through direct
binding of specific r-proteins to the p53 regulator Hdm2 (see below and (9)).
The nucleolus is not limited by a lipid membrane. This makes it a highly dynamic structure that responds
promptly, sometimes by profound morphological and compositional alterations, to cell stresses such as
viral infections, DNA damage, and drug treatments (10,11). During interphase, the nucleoli of amniotic
eukaryotes display three morphologically distinct layers (12, 13), which can be drastically re-organized
under stress (14). During mitosis, the nucleolus undergoes a dramatic cycle of disassembly/reassembly
that parallels Pol I activity controlled by specific phosphorylations (15,16). The number of nucleoli per
cell nucleus and the shape and size of the nucleoli also vary greatly in proliferative diseases such as
cancers (17). Cancer cells are more sensitive than non-cancer cells to inhibition of ribosome synthesis,
and are killed selectively by treatment with Pol I inhibitors (18, 19). Despite the importance of the
nucleolus as a cell stress sensor (20), disease biomarker and target for cancer therapy (21), how its
structural integrity is maintained remains totally unclear.
While the principles of assembly and maintenance of the nucleolus are far from being understood (14),
r-proteins which are very abundant, very basic, and which assemble mostly in the nucleolus onto pre-
rRNAs to form ribosomal subunit precursors are likely to play an important role. The assembly of r-
proteins is not random but follows a precise sequence of events. Groups of r-proteins have been defined
on the basis of their assembly at early, intermediate, or late stages of ribosomal subunit biogenesis (22).
Compromising the timely association of r-proteins with rRNA can indeed lead to severe pre-rRNA
processing inhibitions, ribosomal subunit synthesis abortion, and sometimes to nucleolar structural
alterations visible at the microscopic level (23). To date, no attempt has been made to systematically
address the involvement of r-proteins in nucleolar structure maintenance or to grade their involvement in
this process.
While the nucleolus is a long-known cancer biomarker (17) and a recently demonstrated therapeutic
target (19), it is not widely used by pathologists, however, for lack of reliable clinical assays.
Accordingly, there is a need in the art to improve qualitative as well as quantitative nucleolus assessment,
in order to aid for instance in diagnostics, such as stratification of nucleolar morphology, but as well in
the development of model systems for instance for use in drug development or evaluation, in particular
associated with or otherwise dependent on nucleolar phenotypes, including morphology, such as
nucleolar disruption or nucleolar integrity.
Summary of the invention
An object of the present invention is to provide methods and systems for discriminating populations of
cells (e.g. normal/healthy versus abnormal/disease), for instance based on the analysis of the light
captured by a sensor, when observing each population through an imaging device (e.g. a microscope).
To characterize nucleolar morphology defects both qualitatively and quantitatively, we developed a
specific image-processing algorithm, of which a particular embodiment is detailed below. Briefly, we first
segmented the observed nuclei on the basis of shape- and size-consistent adaptive thresholding of a
nuclear stain (DAPI signal). Then, within each nuclear mass, GFP signal thresholding and mathematical
morphology (see Methods) were applied to segment nucleoli into connected components. In order to
optimize discrimination of nucleoli of cells depleted of an r-protein from those of SCR-treated control
cells, five shape and textural features (or morphometric characteristics) were extracted from the largest
connected components (LCC) of each nucleolus. These five features, selected from a set of eleven as the
most discriminant ones, were: area, elliptical regularity, percentage of pixels below an optimized intensity
threshold, smallest intensity, and number of local minima. For each of the five features, a d value
corresponding to a statistically significant distance between the feature distribution in cells depleted of an
r-protein and control cells was computed. Each population of cells was thus characterized by five d
values. Principal component analysis (PCA) was used to reduce these five dimensions to two, allowing
ready visualization of the data in a scatter plot (Fig. lb) where each dot corresponds to a population of
cells treated with one siRNA.
Here we have depleted human cells systematically of each of the eighty r-proteins and investigated the
consequences on nucleolar structural integrity, pre-rRNA processing, accumulation of mature rRNAs, and
p53 steady-state level (see experimental strategy in Fig. la).
In summary, we show here that depletion of the vast majority of the eighty human r-proteins does not
impact nucleolar structure. This notably applies to nearly all SSU r-proteins (Fig. 1). In striking contrast,
about a third of the LSU proteins appear essential to maintaining normal nucleolar structure. This marked
dichotomy is in line with the notion that pre-40S subunits are exported to the cytoplasm more rapidly than
pre-60S subunits, whose production is more complex and requires numerous additional nuclear
maturation steps. Among the strongest contributors to nucleolar structure are uL5 and uL18, known to
form with 5S rRNA an Hdm2 trap and p53 stabilizer (25,26).
Most r-proteins assemble with pre-rRNAs within the nucleolus, quite early in the subunit assembly
process. Notable exceptions are the acidic proteins uLlO (formerly P0), PI, and P2, which form the P-
stalk on pre-60S subunits only after reaching the cytoplasm in yeast (47). Accordingly, we found the
acidic r-proteins to have no impact on nucleolar structure (Supplementary Fig. 11).
While only a few r-proteins are required for nucleolar structure maintenance, most of them are essential to
pre-rRNA processing (Fig. 4). The processing steps in which r-proteins are involved are primarily those
which lead to synthesis of the rRNAs constituting the subunit to which they belong. The r-proteins whose
depletion has the strongest impact on nucleolar structure are required for late processing reactions in the
pathway of large subunit synthesis (Fig. 2a,b).
Pre-rRNA processing is an excellent proxy of ribosome assembly. Hence, by establishing the precise
involvement of each r-protein in processing, we incidentally extend the conclusion (23,28,30,31,48) that
the sequence of r-protein incorporation into maturing ribosomal subunits, and thus of ribosomal landmark
formation, has been extremely well conserved throughout evolution from bacteria, to yeast and man
(Supplementary Fig. 10). Importantly, we reveal this to be the case for human large ribosomal subunit
assembly. This is quite remarkable, considering the tremendous differences in cell organization, in gene
expression strategies and the increased complexity in ribosomal assembly machineries between
prokaryotes and eukaryotes.
On mature 60S, the r-proteins whose depletion has the strongest impact on nucleolar structure form
specific landmarks: the CP (uL5 and uL18), the LI -stalk, and a region directly below the LI-stalk (Fig.
2). These are late-assembling subunit structures. Furthermore, nucleolar structure is disrupted when uL5
or uL18 incorporation, and hence formation of the CP, is prevented by depletion of specific CP assembly
factors (Fig. 5). We speculate that the importance of these r-proteins in maintaining the integrity of
nucleolar structure reflects the emergence, during evolution, of checkpoints important to cell homeostasis,
ensuring that the late steps of large subunit assembly, and particularly CP formation, occur properly.
Why should CP formation be monitored? Firstly, in the mature ribosome, the CP is involved in
intersubunit interactions beneficial to translation(49,50). Furthermore, CP formation might be tightly
coupled to maturation of essential ribosomal landmarks on the large subunit. This is plausible, given what
is known about CP formation. The 5S RNP is incorporated into maturing 60S subunits as a pre-assembled
block (41), a step aided by the conserved assembly factors Rpf2(yeast)/BXDC1 (human) and
Rrsl/RRSl (26,41,51) (see above). In precursor 60S, however, the 5S RNP does not adopt its final
conformation until it undergoes a 180° rotation (51,52). This rotation seems to act as a power stroke
promoting a cascade of subunit maturation events and the long-range transmission of mechano-chemical
remodeling energy throughout the maturing 60S precursors (52,53). Structures whose formation may be
strictly linked to that of the CP include the conserved A-site finger (ASF) helix 38, which is part of an
intersubunit bridge that monitors the A-site tRNA throughout the decoding process (54), the peptidyl
transferase center itself, where amino-acids are joined together, and possibly the phospho-stalk (52,53).
It is now well established that several r-proteins are essential to regulating the p53 level (9,43). In
principle, depletion of any r-protein is expected to trigger a ribotoxic stress response leading to
accumulation of unassembled ribosomal components, including uL5, uL18, and the 5S rRNA, and to
sequestration of Hdm2. Therefore, it was expected that most r-proteins would be involved, in one way or
another, in regulating the p53 level. In fact, setting a five-fold increase as significance threshold, we
reveal that depletion of any one among two-thirds of the human r-proteins has no significant impact on
p53 accumulation (Fig. 6). Nonetheless, we show that twenty-four r-proteins out of eighty are very
important for p53 homeostasis, their depletion giving rise to a 5-to-10-fold increase in the p53 level. In all
of these cases, the increase in p53 accumulation requires the presence of uL5 and uL18 (Supplementary
Fig. 9). This implies activation of the anti-tumor nucleolar surveillance regulatory loop described above.
Identification of the r-proteins whose depletion affects p53 accumulation provides essential insights into
the etiology of ribosomopathies, which are cancer predisposition syndromes caused by mutations in r-
proteins or by ribosome assembly defects (7).
Up to now, it has been unclear whether the activation of nucleolar surveillance, leading to p53
stabilization, systematically involves disruption of nucleolar structure or simply inhibition of nucleolar
function. Induction of p53 in response to ribosome biogenesis inhibition has indeed been attributed to
nucleolar disruption (55), but studies have also shown that a rise in the cellular level of p53 can occur
after r-protein depletion, independently of gross nucleolar disruption (44,56). This is notably the case
after uL30 (formerly: RpL7) depletion (44). We have confirmed this latter observation, showing that it
applies, in fact, to a large group of twenty-one r-proteins (Table 5).
The nucleolus is a long-known cancer biomarker (17) and a recently demonstrated therapeutic target (19).
It is not widely used by pathologists, however, for lack of reliable clinical assays. The image-processing
algorithm and index of nucleolar disruption (iNo) developed here are robust and versatile tools for
characterizing nucleolar morphological alterations both qualitatively and quantitatively. We have used
them consistently in multiple cell lines, in time course analyses, and with either the dense fibrillar
component or the granular component of the nucleolus (Fig. 3, Supplementary Figs S3,S4). We believe
they hold great diagnostic and prognostic potential in cancer biology and research on ribosomopathies,
several of which involve marked disruption of nucleolar integrity due to r-protein loss or mutation.
The complete dataset and additional information are accessible in a fully searchable information-rich
database at www.RibosomalProteins.com as of the filing date of the present application.
The present invention is in particular captured by the appended claims, which are hereby also
explicitly incorporated by reference.
Figure legends
FIG. 1 : illustrates the systematic screening of human r-proteins, which reveals that uL5 (RPL11) and
uL18 (RPL5) are the strongest contributors to nucleolar structure maintenance. Panel a) Experimental
strategy: All eighty r-proteins were depleted one by one in human cells by use of specific siRNAs. The
nucleolar structure (fluorescence microscopy), the accumulation of mature 18S and 28S rRNAs
(electropherograms), pre-rRNA processing (high resolution northern blotting), and steady-state
accumulation of p53 (fluorescent western blotting) were monitored. Panel b) Principal component
analysis (PCA) showing a classification of r-proteins according to their requirement for nucleolar
structure maintenance. Each r-protein was depleted in three knockdown experiments, each performed
with a different siRNA. The image-processing algorithm that we designed for this analysis involves
selecting five discriminant shape and textural features (or morphometric characteristics), computing five
dk values, and reducing the five dimensions to two by PCA. In the resulting plot, each dot represents one
population of cells treated with one siRNA. Dot intensity is indicative of the targeted protein: black
shapes for small subunit (SSU) r-proteins and white shapes for large subunit (LSU) r-proteins. The mean
of three populations of cells treated with a non-targeting control siRNA (SCR) is indicated with a line
connected to the corresponding image. The grey symbols represent the six calibration controls (FBL,
GFP, NCL, NPM, MOCK, and TIFIA, see Supplementary Fig. 1). Insets show images of the nuclei of
cells depleted of representative proteins with the DNA stained brightly highlighted and the nucleoli
appearing as black shapes (fibrillarin). For a few representative examples, a specific symbol is used (e.g.,
a diamond for uL5). RPS, r-proteins of the SSU; RPL, r-proteins of the LSU. Panel c) r-proteins and
calibration controls classified according to the severity of nucleolar disruption caused by their absence.
The iNo or index of nucleolar disruption was defined as the sum of the dk values of the five most
discriminant shape and textural features identified in this work (LI -norm of the discrepancy vectors
computed from the images presented in our experimental screens of 80 r-proteins (see Example 2).
Higher iNo correspond to more severe disruption. Color-coding as in panel b ; i.e., black for for small
subunit (SSU) r-proteins and white for large subunit (LSU) r-proteins. The gray dots are the means of
three individual experiments. Note: The r-proteins are named according to a recently revised
nomenclature, where the "e" prefix stands for eukaryote-specific and "u" for universal (present in
bacteria, archaea, and eukaryotes).
FIG. 2 : depicts 3D models of human ribosomal subunits based on PDB entries 3J3D, 3J3A, 3J3F, and
3J3B. Late-assembling r-proteins of the large subunit are the strongest contributors to nucleolar structure
maintenance and p53 homeostasis. The r-proteins are color-coded according to the impact of their
depletion on nucleolar structure (iNo values) (a), pre-rRNA processing (b), or the p53 steady-state level
(c). Left, subunit interface views; right, solvent-exposed views. The aminoacyl (A), peptidyl (P), and exit
(E) tRNA sites are indicated. Morphological features of the subunits are highlighted. On the
LSU: the Ll-stalk, central protuberance (CP), and phospho-stalk (P-stalk). On the SSU, the beak (Be),
head (H), platform (Pt), body (Bd), left foot (Lf), and right foot (Rf).
FIG. 3 : illustrates the quantitative monitoring of nucleolar morphology in different human cell lines,
based on detection of endogenous PES1. The data show, for a selection of eight representative r-proteins,
that the r-proteins contributing weakly or strongly to nucleolar structure maintenance are largely the same
in multiple cell lines.
(a) The indicated r-proteins were depleted with an siRNA for 3 days in two cervical carcinoma cell lines
(HeLa-GFP-FBL, engineered to express fluorescent fibrillarin, and genetically unmodified HeLa), one
colon carcinoma cell line (HCT116), and two lung carcinoma cell lines (A549 and HI944). Endogenous
PES1 was detected by immunostaining with a specific antibody (see Example 1). As a control, cells were
treated with a non-targeting control siRNA (SCR) and depleted of NPM (see also Supplementary Fig. 1).
(b) Values of the nucleolar disruption index (iNo) obtained after 3 days of siRNA-mediated depletion of
the indicated r-protein as calculated on the basis of the endogenous PES 1 signal.
FIG. 4 : depicts schematically the involvement of human r-proteins in pre-rRNA processing (a) The
28S/18S ratio calculated from Agilent bioanalyzer electropherograms. Data are shown for the two
different siRNAs used (siRNA # 1 and #2). (b) Major pre-rRNA intermediates and probes used in this
work. Three of the four rRNAs are produced by RNA Pol I as a long 47S primary transcript. The 18S,
5.8S, and 28S rRNAs are separated by noncoding external (ETS) and internal (ITS) transcribed spacers.
Probes a, b, and c are the oligonucleotides LD1844, LD1827, and LD1828, respectively (see Example 1).
(c) Pre-rRNA processing inhibitions upon depletion of SSU r-proteins. On the northern blots (see
Supplementary Figs S5,S6, Sll), all RNA species were quantified with a Phosphorimager, normalized
with respect to the non-targeting control (SCR), and their abundances represented on a heatmap using the
color code indicated. The heatmap profiles were clustered with "R" and the corresponding proteins
grouped in classes of r-proteins affecting the same or similar processing steps. The different siRNAs used
are indicated (#). Asterisks refer to r-proteins assigned to two groups according to the siRNA used (d) As
in panel c for LSU r-proteins.
FIG. 5 : reveals the central protuberance assembly factors BXDC1 and RRS1 are required for nucleolar
structure integrity (a) Cells expressing fibrillarin fused to the fluorescent protein were treated for 3 days
with an siRNA targeting transcripts encoding the indicated protein. Two independent siRNAs (#1 and #2)
were used in each case. Cells treated with a non-targeting (SCR) siRNA control are shown for reference
(b) For each depletion, the nucleolar disruption index (iNo) was calculated (see Fig. 1 and Example 1).
FIG. 6 : illustrates the involvement of human r-proteins in p53 homeostasis (a) Steady-state level of p53
determined by quantitative fluorescent western blotting. Western blots analysis are shown for
representative r-proteins, with the p53 level indicated underneath as a mean of biological triplicates
obtained after treatment of cells with the same siRNA (i, ii, and iii). The siRNA used was selected on the
basis of its proven efficacy in the processing and nucleolar screens (Figs 1 and 4). The p53 signal
corrected for loading (using β-actin as reference) was expressed with respect to the level observed in cells
treated with a non-targeting siRNA control (p53 +/+). The upper signals correspond with p53; the
bottom signals with β-actin. A complete data set for all eighty r-proteins is available in Supplementary
Fig. 11. As loading control we used HCT116 p53+/+ cells transfected with a non-targeting siRNA (p53
+/+) providing the basal level of p53 or with an antisense oligonucleotide suppressing the activity of the
box C/D snoRNA U8 (#U8), thereby stimulating p53 accumulation up to 6-fold (J.-L.L, E.N. and
D.L.J.L., submitted). As background control, we used a matched isogenic HCT116 cell line that does not
express p53 (HCT116 p537-, ref.39) treated with a non-targeting siRNA (p53 -/-).
(b) r-proteins classified according to their impact on the p53 steady-state level. The non-targeting (SCR)
control is shown in black, the SSU r-proteins in white, and the LSU r-proteins in grey. The histogram bars
are the means of triplicates with SD. r-proteins whose depletion leads to a 5-fold increase in p53 level are
highlighted in a gray box.
Supplementary FIG. 1 : The nucleolar calibration set. The calibration set used consisted of four control
proteins whose depletion, we established, strongly disrupts nucleolar structure. These control proteins are:
the RNA polymerase I (Pol I) transcription factor TIF1A, nucleolin (NCL), and nucleophosmin (NPM).
As further standardization controls, we used mock-treated (MOCK) cells, cells treated with an siRNA
targeting FBL or GFP, and cells treated with a non-targeting siRNA (SCR). White signal, DNA stain
(DAPI); black signal within white, GFP. Left column, images captured at 20x magnification in widefield
mode. Right column, images captured at 40x magnification in confocal mode. To the right of these
images, schematics depicting the effect of siRNA-mediated depletion on nucleolar structure and signal
intensity.
Supplementary FIG. 2 : Benchmarking the automated unsupervised classification of nucleolar disruption
phenotypes. To benchmark our novel classification algorithm, we compared the automated classification
described in the text with a manual one. The manual classification was based on the fine visual inspection
of representative images obtained after depletion with each siRNA used and on the assignment of
nucleolar disruption phenotypes to three arbitrarily defined classes corresponding to weak, intermediate,
and strong disruption. Superimposition of the automatically and manually obtained classifications made
us highly confident that assignment to phenotypic classes on the basis of our automated procedure is
robust (a) PCA (see Fig. lb). Each circle represents a population of cells treated with one siRNA specific
to one r-protein. The circles are intensity-coded according to a manual classification based on the fine
visual inspection of the microscopic images. The non-targeting control (Scramble, SCR) is indicated with
an arrow. Strong contributors to nucleolar structure maintenance are black; intermediate contributors are
in grey; weak contributors are in white (b) Representative images illustrating the manual classification of
r-proteins as weak, intermediate, and strong contributors to nucleolar structure maintenance. White signal,
DNA stain; black signal, fibrillarin.
Supplementary FIG. 3 : Kinetics of nucleolar disruption after siRNA-mediated r-protein depletion. The
data show that the computed iNo values reliably reflect phenotype severity, and that nucleolar disruption
is best scored in cells having undergone two successive rounds of nucleolar breakdown/nucleolar genesis,
corresponding to two cell divisions (~72h). (a) Values of the nucleolar disruption index (iNo) obtained
after siRNA-mediated depletion of the indicated r- protein for 24 h, 48 h, and 72 h, which are white,
grey, and black, respectively (b) Representative images for thirteen r-proteins tested at each time point.
White signal, DNA stain; Black signal, fibrillarin. # 1 refers to the siRNA used (see Example 1).
Supplementary FIG. 4 : Quantitative monitoring of nucleolar morphology based on detection of the
endogenous granular component marker PES1. The data show that the iNo values can be computed
equally on the basis of DFC (fibrilarin, FBL) or GC (PES1) antigen detection (a) Values of the nucleolar
disruption index (iNo) obtained after 3 days of siRNA-mediated depletion of the indicated r-protein as
calculated on the basis of the fibrillarin signal (white bars) or the PES1 signal (black bars) (b)
Representative images for the thirteen r-proteins tested. In each case the siRNA n°l (#1) was used (see
Example 1). White signal, DNA stain; black signal, fibrillarin (top rows) or PES1 (bottom rows).
Supplementary FIG. 5 : Involvement of small subunit r-proteins in pre-rRNA processing (a)
Representative examples of northern blots for each of the three classes of SSU r-proteins defined in this
work (for a full dataset see Supplementary Fig. 11). A calibration set consisting of mock-treated cells and
cells treated with a non-targeting siRNA (SCR) or a siRNA targeting UTP18 or NOL9 was used
systematically (see ref.l). Schematics of the RNA intermediates detected are shown on the left. Ratios of
28S to 18S mature rRNA were calculated from bioanalyzer electropherograms. (b) Expanded version of
Fig. 4c, showing all RNA intermediates detected and quantified.
Supplementary FIG. 6 : Involvement of large subunit r-proteins in pre-rRNA processing (a)
Representative examples of northern blots for each of the four classes of LSU r-proteins defined in this
work (for a full dataset see Supplementary Fig. 11). A calibration set consisting of mock-treated cells and
cells treated with a non-targeting siRNA (SCR) or a siRNA targeting UTP18 or NOL9 was used
systematically (see ref.l). Schematics of the RNA intermediates detected are shown on the left. 28S/18S
mature rRNA ratios were calculated from bioanalyzer electropherograms. (b) Expanded version of Fig.
4d, showing all RNA intermediates detected and quantified.
Supplementary FIG. 7 : Comparison of our classification of r-proteins according to their involvement in
pre-rRNA processing with previous studies. The figure shows that our work either confirms (small
subunit r-proteins) or considerably complements (large subunit r-proteins) the literature. 3-D models of
human ribosomal subunits based on PDB entries 3J3D, 3J3A, 3J3F, and 3J3B. Left, subunit interface
views; right, solvent-exposed views. The aminoacyl (A), peptidyl (P), and exit (E) tRNA sites are
indicated. Morphological features of the subunits are highlighted. On the LSU: the Ll-stalk, central
protuberance (CP), and phospho-stalk (P-stalk). On the SSU, the beak (Be), head (H), platform (Pt), body
(Bd), left foot (Li), and right foot (Rf). (a) Previous studies: conducted on cervix cancer cells where p53
expression is disrupted by HPV integration (HeLa cells). The SSU r-proteins were tested in ref. 2; six out
of the forty-seven LSU r-proteins were tested in ref. 3. (b) This work: conducted on colon carcinoma cells
expressing p53 normally (HCT116 p53+/+)(based on Fig. 4 and Supplementary Figs. S5,S6,S11). All r-
proteins were tested.
Supplementary FIG. 8 : Efficiency of r-protein depletion established at the mRNA level by RTqPCR.
For forty-eight r-proteins whose depletion did not significantly affect p53 accumulation (see Fig. 6b), the
residual level of mRNA was established by RTqPCR and found to be below 20% for forty of
them, and to range between 20% and 45% for the remaining eight. Total RNA was extracted from
HCT116 cells treated for 2 days with an siRNA specific to transcripts encoding the indicated r-proteins.
Residual levels of mRNA were established by RTqPCR and normalized to those observed in cells treated
with a non-targeting siRNA control (SCR). Each experiment was performed in triplicate.
Supplementary FIG. 9 : Depletion of twenty-four r-proteins out of eighty leads to a significant five-fold-
increased level of p53, and this increase requires the presence of uL5 and uL18. HCT116 p53+/+ cells
were depleted for 2 days with an siRNA specific to transcripts encoding the indicated protein. Each
protein was depleted by itself, or in combination with uL18 or uL5 depletion. As control, cells were
treated with a non-targeting siRNA (SCR). Total protein was extracted and processed by western blotting
with antibodies targeting p53, p21 (a transcriptional target of p53), and, as loading control, β-actin. Bands
were revealed by luminescence (a) Effect of individually depleting each of the 24 r-proteins. (b) Effect of
depleting the central protuberance assembly factor BXDC1 or RRS1.
Supplementary FIG. 10: The sequence of assembly of r-proteins onto assembling ribosomal subunits
has been remarkably conserved throughout evolution (a) 3-D models of bacterial ribosomal subunits
based on PDB entries 2AVY and 2AW4. The r-proteins are intensity-coded according to their early,
intermediate, or late order of assembly, as established in vitro (refs 4-8). (b) 3-D models of budding yeast
ribosomal subunits based on PDB entries 3U5B, 3U5C, 3U5D, and 3U5E. The r-proteins are labeled on
the basis of their being required for specific early, intermediate, or late pre-rRNA processing steps in
yeast cells (refs 9, 10). This largely corresponds to their kinetics of assembly established in vivo (ref. 11).
(c) 3-D models of human ribosomal subunits based on PDB entries 3J3D, 3J3A, 3J3F, and 3J3B. The r-
proteins are classified with respect to their impact on specific processing reactions in human cells
according to this work (based on Fig. 4, Supplementary Figs. S5,S6,S11). Left, subunit interface views;
right, solvent-exposed views. The aminoacyl (A), peptidyl (P), and exit (E) tRNA sites are indicated.
Morphological features of the subunits are highlighted. On the LSU: the Ll-stalk, central protuberance
(CP), and phospho-stalk (P-stalk). On the SSU, the beak (Be), head (H), platform (Pt), body (Bd), left
foot (Lf), and right foot (Rf).
Supplementary FIG. 11: An example of a complete data sheet for one r-protein. The datasheets for all
the eighty human r-proteins is available on the companion website at www.ribosomalProteins.com. The
data sheet shows the position of the r-protein on mature subunit (A), its impacts on pre-rRNA processing
and mature rRNA accumulation (B), on nucleolar structure (C), and on the p53 steady-state level (D).
(A) 3-D models of human ribosomal subunits based on PDB entries 3J3D and 3J3A, for SSU r-proteins,
and 3J3F and 3J3B, for LSU r-proteins. The positions of individual r-proteins on the mature subunits are
highlighted. On small subunits, the 18S rRNA is shown in gray; on large subunits, the 5S, 5.8S, and 28S
rRNAs are shown in red, blue, and gray, respectively. Left, interface view; right, solvent view. The main
ribosomal features are indicated (see Supplementary Fig. 10). (B) Effects of r-protein depletion on pre-
rRNA processing and mature rRNA accumulation: northern blots and ethidium-bromide-stained
denaturing agarose gels showing all the pre-rRNA intermediates and mature rRNAs detected. The
28S/18S rRNA ratio was calculated from electropherograms. A calibration set (described in
Supplementary Figs S5,S6) is included for reference. Schematics representing the RNAs detected are
shown to the left. Quantifications are available in Fig 4. and Supplementary Figs S5,S6. (C) Effect of r-
protein depletion on nucleolar structure: representative microscopic images (blue signal, DAPI; green
signal, fibrillarin) obtained after treatment in duplicate screens (i and ii) performed with three different
siRNAs (#1, #2, and #3). iNo values for each screen are indicated to the right and on a scaled bar at the
bottom. The iNo value ranges between 0 (unperturbed nucleolus) and 0.2 (severely disrupted structure).
(D) Effect of r-protein depletion on the p53 steady-state level: fluorescent quantitative western blotting
was performed in triplicate (i, ii, iii). The p53 signal was corrected for loading, using D-actin detection as
a reference, and expressed with respect to the signal obtained in cells treated with a non-targeting (Scr)
control (lane 2). The p53 signal was expressed as a mean of three independent experiments (see Fig. 6 for
details). A calibration set (described in Fig. 6) is included for reference.
Supplementary FIG. 12: Examples of uncropped Northern blots. An example of a high resolution
denaturing agarose gel is shown (a) Ethidium bromide staining reveals the mature 18S and 28S rRNAs.
(b,c,d) Northern blotting with specific probes reveals the pre-rRNAs. All RNA species were identified by
differential hybridization with specific probes, and by reference to a calibration set consisting of two
proteins (UTP18 and NOL9) whose depletion leads to well-characterized pre-rRNA processing
inhibitions, as described in ref. 1. The probes used (ITSl in b, ITS2 in c, and 5' -ETS in d) are described
in Example 1. Lane 1, mock; lane 2, SCR; lane 3, UTP18; lane 4, NOL9; lane 5, uS3; lane 6, uS17; lane
7, uL30#l; lane 8, uL30#2; lane 9, uL13#l; lane 10, uL13#2; lane 11, eL14#l; lane 12, eL14#2; lane 13,
ul22#l; lane 14, ul22#2; lane 15, eL18#l; lane 16, eL18#2; lane 17, eL22#l; lane 18, eL22#2; lane 19,
uL14#l; lane 20, uL14#2; lane 21, uL24#l; lane 22, uL24#2. # 1 and #2 refer to the siRNAs used (see
Example 1).
Supplementary FIG. 13: Examples of uncropped Western blots. All western blot hybridizations
performed in this work used well-characterized commercially available antibodies (see Example 1). On
fluorescent (a) and luminescent (b) detections, p53 migrated between the 35 kDa and the 55 kDa
molecular weight bands, as expected (p53 has a molecular weight of 43.7 kDa). The p53 signal was
increased upon nucleolar stress activation (U8 depletion in a, and uLl depletion in b, by comparison to
the signals observed in cells treated with a non-targeting Scr control). The p53 level was severely reduced
upon codepletion of uLl with uL5 or uL18 (b). On the fluorescent screening gels (representative
examples shown in c), the β-actin loading control (bottom rows) was detected as a single band
immediately below the p53 signal, as expected (β-actin has a molecular weight of 42 kDa). The p53 band
(top row) was consistently detected at low levels in the duplicated HCT116 p53 +/+ cells treated with a
non-targeting siRNA (p53 +/+ lanes), this served as a baseline control. The p53 levels increased
substantially upon nucleolar stress caused by U8 snoRNA depletion (#U8 lanes), this served as a positive
control. The p53 band was never detected in the negative control provided by the HCT116 p53 -/-
isogenic cell line (p53 -/-). The stars denote nonspecific bands.
Supplementary FIG. 14: Nuclei aggregates are eliminated on the basis of a shape convexity
analysis. Two segmented juxtaposed nuclei are illustrated. In the direction of the principal axis X and Y,
if 8out, δ ΐ η, and 82in are above a threshold on one of the lines parallel to the principal axis, the shape is
considered to include more than one nucleus.
Supplementary FIG. 15: Results of segmentation of nuclei for highly contrasted (a) and weakly
contrasted (b) DAPI images. The connected components are detected based on the proposed hierarchical
thresholding. Irregular regions are rejected because of their concavity. Some regions are rejected because
the DAPI/GFP intensity analysis indicates that cells are probably not in interphase. Only remaining nuclei
circled are maintained in our analysis, and for the subsequent analysis, we consider the segmentation,
obtained after morphological operations: 13x13 dilation, followed by 3x3 erosion.
Supplementary FIG. 16: Samples of nucleoli from SCR-treated control cells (a), from cells with a range
of high level of nucleolar disruption (b) and from cells depleted of a specific protein of interest (c). Cell
nuclei in each column were treated with the same siRNA. Images were normalized by percentile 99.9%.
Supplementary FIG. 17: Fibrillarin-GFP intensity profile of nucleoli in a SCR-treated control cell (a) or
in a cell depleted for the protein uL5 (b). (a) corresponds to the nucleus in row 1, column 2 in
Supplementary Fig. 16, panel a. (b) corresponds to the nucleus in row 1, column 5 in Supplementary Fig.
16, panel c .
Supplementary FIG. 18: Illustration of the shape factors associated to a connected component C (inner
shape black contour) (a) The elongation factor reflects the ratio between the principal axes second order
moments, while the elliptical regularity measures the area ratio of the smallest external ellipsoid C ps
(outer shape in grey contour) to the connected component (b) The concavity ratio measures the area ratio
between the convex hull C
∞ v uii (outer shape in grey contour) and the connected component.
Supplementary FIG. 19: Distribution of local maxima (white dots) and local minima (black dots) in the
images shown in Supplementary Fig. 16. It is apparent that the density of local minima is higher in
nucleoli from cells with high level of nucleolar disruption (panel b) or from cells depleted of a protein of
interest (panel c) than in nucleoli from SCR-treated control cells (panel a).
Supplementary FIG. 20: Fisher's optimization criterion as a function of three features (a, b, and c)
parameters.
Detailed description
Before the present system and method of the invention are described, it is to be understood that this
invention is not limited to particular systems and methods or combinations described, since such systems
and methods and combinations may, of course, vary. It is also to be understood that the terminology used
herein is not intended to be limiting, since the scope of the present invention will be limited only by the
appended claims.
As used herein, the singular forms "a", "an", and "the" include both singular and plural referents unless
the context clearly dictates otherwise.
The terms "comprising", "comprises" and "comprised of" as used herein are synonymous
with "including", "includes" or "containing", "contains", and are inclusive or open-ended and do not
exclude additional, non-recited members, elements or method steps. It will be appreciated that the terms
"comprising", "comprises" and "comprised of" as used herein comprise the terms "consisting of,
"consists" and "consists of".
The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the
respective ranges, as well as the recited endpoints.
The term "about" or "approximately" as used herein when referring to a measurable value such as a
parameter, an amount, a temporal duration, and the like, is meant to encompass variations of +/-10% or
less, preferably +1-5% or less, more preferably +/-!% or less, and still more preferably +/-0.1% or less of
and from the specified value, insofar such variations are appropriate to perform in the disclosed invention.
It is to be understood that the value to which the modifier "about" or "approximately" refers is itself also
specifically, and preferably, disclosed.
Whereas the terms "one or more" or "at least one", such as one or more or at least one member(s) of a
group of members, is clear per se, by means of further exemplification, the term encompasses inter alia a
reference to any one of said members, or to any two or more of said members, such as, e.g., any >3, >4,
>5, >6 or >7 etc. of said members, and up to all said members.
All references cited in the present specification are hereby incorporated by reference in their entirety. In
particular, the teachings of all references herein specifically referred to are incorporated by reference.
Unless otherwise defined, all terms used in disclosing the invention, including technical and scientific
terms, have the meaning as commonly understood by one of ordinary skill in the art to which this
invention belongs. By means of further guidance, term definitions are included to better appreciate the
teaching of the present invention.
In the following passages, different aspects of the invention are defined in more detail. Each aspect so
defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In
particular, any feature indicated as being preferred or advantageous may be combined with any other
feature or features indicated as being preferred or advantageous.
Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular
feature, structure or characteristic described in connection with the embodiment is included in at least one
embodiment of the present invention. Thus, appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not necessarily all referring to the same
embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined
in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or
more embodiments. Furthermore, while some embodiments described herein include some but not other
features included in other embodiments, combinations of features of different embodiments are meant to
be within the scope of the invention, and form different embodiments, as would be understood by those in
the art. For example, in the appended claims, any of the claimed embodiments can be used in any
combination.
In the present description of the invention, reference is made to the accompanying drawings
that form a part hereof, and in which are shown by way of illustration only of specific embodiments in
which the invention may be practiced. Parenthesized or emboldened reference numerals affixed to
respective elements merely exemplify the elements by way of example, with which it is not intended to
limit the respective elements. It is to be understood that other embodiments may be utilised and structural
or logical changes may be made without departing from the scope of the present invention. The following
detailed description, therefore, is not to be taken in a limiting sense, and the scope of the present invention
is defined by the appended claims.
In an aspect, the invention relates to a method for characterizing nucleolar morphology, architecture, or
integrity, comprising measuring or determining one or more morphometric characteristics of the nucleolar
support area and the nucleolar intensity pattern. In certain embodiments, the morphometric characteristics
are defined by parametric functions. In certain embodiments, the method comprises characterizing, in a
measurable and quantifiable manner, the visual appearance of the nucleolus in an image, including
morphology or form (encompassing size, shape, and number of subcomponents) and inner pattern
structure (encompassing spatial organization and spatial variation of pixel intensity).
For example, individual cell nuclei and/or cell nucleoli may be segmented based on light intensity
captures. Light intensity also reveals the nucleolar masses composing each cell nucleolus. Each
population of cells may be described by the stochastic distributions of a set of discriminant nucleolar
features (i.e. morphometric characteristics). A nucleolar feature is a scalar value that reflects one
particular aspect of the spatial organization of nucleolar masses within one individual cell nucleus.
In certain embodiments, a feature discriminates between two populations of cells when the statistical
distribution of the feature values measured over the two populations have a limited overlap, as for
example measured by a large difference of averages compared to their mean standard deviation.
A set of nucleolar features that discriminate between two types of cell populations may in an aspect or an
embodiment be derived in the following steps:
1) A set of arbitrary parametric features is defined, e.g. by an expert in the field, to capture the main
salient differences observed between representative nucleoli samples of each population;
2) The parameters associated to each feature are then selected to minimize the overlap between pairs of
exemplars of the populations to discriminate;
3) Only the features, and their associated parameters, leading to a large separation between populations
are kept as discriminant features.
In an embodiment, such method comprises the steps of:
a) defining a set of arbitrary parametric morphometric characteristics to capture the most salient
morphometric differences observed between representative nucleoli samples of two populations of
interest;
b) selecting the parameters associated to each morphometric characteristic to maximize their
discriminating power and/or to minimize the overlap between the morphometric characteristic
probabilistic distributions derived from each population, preferably according to Fisher's criterium; and
c) selecting the morphometric characteristics and their associated optimized
parameters leading to a large separation between populations to discriminate;
d) computing the distance between the two cells or cell populations based on a combination, e.g.
using a weighted summation, of the distances measured in terms of the selected morphometric
characteristics.
Accordingly, in an aspect, the invention relates to the use of the above method for identifying features
that discriminate between two types of cell populations, such as identifying features that discriminate
between two types of cell populations with different nucleolar morphology or architecture.
As an example to distinguish populations of cells with regard their nucleolar morphology, the present
invention provides in certain embodiments a set of selected parametric features, their optimization, and
combination. In certain embodiments, the combination results in the (weighed) sum of the absolute value
of a normalized distance between the feature distributions (e.g. the Fisher score) associated to the
population of cells we want to compare. Other features and combinations are possible.
The features that are envisioned to capture the main salient differences between the light intensity patterns
revealing the nucleolar structure of cell samples are in certain embodiments:
• Features that characterize the size and/or shape of the spatial support of the nucleolar masses.
Those features preferably count the number of distinct connected components contributing to the nucleoli,
and/or the number of pixels that are part of each of those components. They may also include any
quantitative metric that reflects the elongation and/or elliptical regularity and/or concavity of the
nucleolar masses. All those features are preferably parametrized by the level of light intensity above
which a pixel is considered to be part of the nucleolar masses.
• Features that characterize the spatial variation of the nucleolar signal within the nucleolar
connected components. Spatial variations may be measured inside and/or on the boundary of connected
components. In the neighbourhood of the boundary of a connected component, the sharpness of transition
of nucleolus-related light intensity between the nucleolar mass and the background image may be
measured. Inside a connected component, the features may be defined to capture the spatial variations of
light intensities. In practice, the magnitude and number of local minima and local maxima of nucleolus-
related light intensity values may be considered, as well as in addition or in the alternative the number of
pixels having a relatively small intensity value and/or the number and shape of high intensity sub-regions
that are separated by small intensity valleys inside a connected component. All those features may be
parametrized by the thresholds adopted to define the notions of small/high intensity, and/or by the
structuring elements considered to define the notions of inside/outside a component, preferably based on
mathematical morphology.
As used herein, the terms "morphology" and "architecture" may generally refer to the overall appearance
of nucleoli, such as for instance identified on images of cells or tissues "nucleolar integrity" and the
related "nucleolar disruption" may generally refer to the similarity or dissimilarity of the nucleolar
morphology or architecture in a sample cell (population) or tissue compared to a reference nucleolar
morphology or architecture. Preferably, such reference nucleolar morphology or architecture is a
"normal" nucleolar morphology or architecture, e.g. the nucleolar morphology or architecture of
non-diseased cells, or cells known not to have an abnormal nucleolar morphology or architecture (and as
such may also include diseased cells, but which do not have an abnormal nucleolar morphology or
architecture). In certain embodiments, a standard or reference nucleolar morphology may be cell type
specifically determined (e.g. for neuronal cells, epithelial cells, etc.). As used herein, the term
"morphometric characteristic" may generally refer to any feature capable of describing the visual
appearance, including morphology or form (encompassing size and shape) and inner pattern structure
(encompassing spatial organization and variation), and which is measurable and quantifiable.
The term "nucleolar support area" may generally refer to the physical location of the nucleolus, or the
area enclosing a nucleolus, e.g. on an image, as defined herein elsewhere. The term "nucleolar intensity
pattern" may generally refer to specific intensity-associated morphometric features and their distributions,
as described herein elsewhere.
In certain embodiments, the morphometric characteristics are determined on images of cells, cell
populations, or tissues. In certain embodiments, the morphometric characteristics are determined on
images of tissue sections. Cells or tissues may be prepared by techniques known in the art, and which
allow cell or tissue imaging. In certain embodiments, the images are or include fluorescent components,
e.g. DAPI, for nuclear staining, or fluorescent labels (e.g. antibodies) for specific cell structures or
molecules (e.g. nucleolus-specific components, structures, or molecules). The present invention is
however not limited to the use of fluorescent imaging. The skilled person can readily envisage alternative
imaging methods and techniques. Also in vivo imaging methods are possible in certain embodiments
according to the invention (see for instance US 2015/157254).
In certain embodiments, the method according to the invention as described herein is used to
quantitatively score nucleolar morphology, architecture, integrity, or disruption.
In certain embodiments, the method according to the invention as described herein is used to qualitatively
or quantitatively classify, score, diagnose, and/or grade disorders underlying and/or characterized by
nucleolar disruption, or abnormal nucleolar morphology or architecture. In certain embodiments, such
disorder is cancer, autoimmune disease, viral infection, neurodegenerative disorder, or ribosomopathy
(such as cancer predisposition, skeletal problems, or hematological problems).
In certain embodiments, the according to the invention as described herein is used to classify, score,
diagnose, and/or grade a cell (population) or tissue, based on the severity of nucleolar disruption, or the
deviation or difference of nucleolar integrity compared to a standard or reference.
In certain embodiments, the characterization of nucleolar morphology according to the invention as
described herein is associated with or underlies a particular prognosis.
In certain embodiments, the characterization of nucleolar morphology according to the invention as
described herein is associated with or underlies a particular treatment plan.
In an aspect, the invention relates to a method for scoring, quantifying, or classifying nucleolar disruption
and/or for determining and/or prognosing the health status of an individual or of a cell or tissue or for
diagnosis, comprising performing the method according to the invention as described herein. In certain
embodiments, the iNo value as described herein elsewhere is indicative of the severity of said
nucleolar disruption, or the severity or grade of said health status. In certain embodiments, said health
status or diagnosis is indicative of cancer/tumor/malignancy/proliferative disease or disorder (or pre-
cancerous/pre-neoplastic/pre-malignant disorders or stages, such as hyperplasia, dysplasia, or metaplasia),
autoimmune disease, viral infection, neurodegenerative disorder, or ribosomopathy (such as cancer
predisposition, skeletal problems, or hematological problems).
In certain embodiments, said method comprises obtaining or providing a cell or tissue sample of a subject
or patient.
In an embodiment, the invention relates to a method according to the invention as described herein,
comprising the steps:
a) obtaining or providing an image of one or more eukaryotic cell, or eukaryotic tissue, or
preferably of a population of cells ;
b) optionally segmenting said image thereby obtaining individual cells or cell nuclei;
c) segmenting said image, thereby obtaining one or more nucleolar masses, preferably comprising
a plurality of connected pixels, which connected pixels constitute or represent a nucleolar connected
component;
d) optionally assigning by colocalization nucleolar masses to individual cells or cell nuclei and
thus to individual cells;
e) extracting one or more feature (i.e. morphometric characteristic) characterizing the support
area, and the intensity pattern of connected components;
f) computing probabilistic distributions of said features (e.g. for cell populations); and
g) comparing said probabilistic distributions with a reference model distribution and/or
determining the overlap of said probabilistic distributions to a reference model distribution.
In the above method, b) and/or d) may both be optional. The method above may thus comprise b); b) and
d); d); or none of b) and d).
As used herein, the term "connected pixels" refers to adjacent or neighbouring pixels on a graph or image,
i.e. pixels which are next to each other (in any direction). According to certain embodiments, the set of
connected pixels (and hence by extension the segment or component or connected segment or
component) are or comprise or consist of adjacent pixels each having an intensity above a given
threshold. Each pixel is a node, and the graph or image edges are directly derived from the definition of a
neighborhood system, which typically assigns 4 (top, down, left, right) or 8 neighbors (4 + oblique
directions) to each pixel. A connected component (or just component) of an undirected graph or image is
a subgraph or subimage in which any two vertices are connected to each other by paths, and which is
connected to no additional vertices in the supergraph or superimage. A vertex with no incident edges is
itself a connected component. Hence, a nucleolar connected component is a set of nucleolar pixels in
which any two pixels can be connected through a path (a sequence of pixel adjacency relationships) that
only include nucleolar pixels.
In certain embodiments, such method further comprises treating a subject if the nucleolar
morphology is determined to be affected, abnormal, or disrupted.
In an embodiment, as an initial step to delimit cell nucleoli from individual cells, the cell nucleus is
segmented. Each cell has a single nucleus. The nucleoli are specialized subnuclear domains, which, by
definition, are all contained within the nucleus. Segmenting the nucleus, which is dense, compact and
easy to score, is thus a mean to delimit the cellular volume that contains nucleoli in each individual cell.
Nuclei may in certain embodiments be stained with a DNA stain, such as for example, and without
limitation with DAPI. The nuclei contours may in certain embodiments be extracted from the DAPI
channel (or other stain or means of visualization of the nucleus) in two steps. Firstly (step 1), large
connected components of relatively high intensity are identified using a thresholding method, such as for
instance an adaptive thresholding method as described in Example 2. Optionally secondly (step 2), the
connected components that show significant concavity, indicating they likely correspond to aggregated
nuclei, may be rejected in certain embodiments.
Step 1 may in certain embodiments consist in a stepwise thresholding of the DAPI images (or other stain
or means of visualization of the nucleus) such that nuclei corresponding to sufficiently large connected
components of pixels lying above an intensity threshold are selected. To address stochastic variation, in
certain embodiments, a hierarchical thresholding strategy may be adopted that progressively refines the
segmentation by considering a sequence of increasing thresholds, while exploiting prior knowledge about
the size range of human cell nuclei.
In step 2, the rejection of the connected components that likely correspond to multiple nuclei is
considered. For this, in certain embodiments, the convexity of each connected component is analyzed. By
means of example, and without limitation, in certain embodiments, a number of lines are drawn in parallel
to the two principal axis of the connected component. When the connected component is convex, either
one or zero segment lies inside the contour, for all parallel lines. In contrast, when the connected
component represents aggregated nuclei, it presents a strong concavity and there exist parallel lines that
include two or more segments lying inside the contour. If one parallel line supports two sufficiently long
inner segments that are separated by a sufficiently long outer segment, the connected component is
rejected. In certain embodiments, a threshold, such as a threshold of a particular number of pixels is set
based on which is determined the length of inner and outer segments in order to include or exclude
particular components. Those lengths in certain embodiments have to be larger than a threshold of for
instance at least 1, 2, 3, 4, or preferably at least 5 pixels to reject the component. The threshold value may
in certain embodiments be set empirically to drastically reduce the number of multiple nuclei while
keeping most of the single nuclei, compared to a manually generated ground truth.
In certain embodiments, only cells in interphase are analyzed. To identify them, in certain embodiments,
the DAPI image (or other stain or means of visualization of the nucleus) and/or the distribution of
nucleolus-specific stain (or other means of visualization of the nucleolus) in the segmented component
are considered. A cell in certain embodiments is considered to be in interphase if the DAPI (or other stain
or means of visualization of the nucleus) is sufficiently dense and spread (if for example at least 50% of
the pixels in the nucleus have a normalized DAPI value larger than 0.3, preferably larger than 0.4,
more preferably larger than 0.47, with the DAPI image (or other stain or means of visualization of the
nucleus) being normalized by its maximal value), and/or if the nucleolus specific stain (or other means of
visualization of the nucleolus) is sufficiently localized (if at least 50% of the pixels in the nucleus have a
normalized nucleolus specific stain (or other means of visualization of the nucleolus) value lower than
0.7, preferably lower than 0.6, more preferably lower than 0.53, with the nucleolus specific stain (or other
means of visualization of the nucleolus) image being normalized by its maximal value). The thresholds in
certain embodiments are set on the basis of a manual ground truth annotation of the images.
Finally, as a post-processing step, in certain embodiments, to ascertain all nucleoli of a cell are contained
in each segmented regions, a basic mathematical morphology to close and enlarge each connected regions
is applied. In certain embodiments, a dilation by a 13 x 13 structuring element is followed by a 3 x 3
erosion.
In certain embodiments, the morphometric characteristics as defined herein are independent of the actual
position of the nucleoli within the nucleus. In certain embodiments, the morphometric characteristics as
defined herein while (still) reflect the spatial spreading of the nucleolar masses. In certain embodiments,
those characteristics are defined based on a manually-selected set of image samples, depicting typical
normal and abnormal nucleolus patterns. The manual extraction of representative samples in certain
embodiments allows to derive features that are relevant to make sure that the set of investigated features
are able to discriminate among the variety of nucleolus appearances. In certain embodiments, each
characteristic is systematically defined as a parametric function (advantageously so that its parameters can
be optimized over the entire database to make the feature can differentiate between normal and gene-
depleted cells images).
In certain embodiments a set of manually-selected cells nucleoli images that are representative of the
appearance diversity in reference control cells is selected (cf. Supplementary Fig. 16). In addition, or in
the alternative, in certain embodiments, a 2-D or 3-D graph representing nucleolar intensity may be use to
visualize nucleolar appearance diversity.
In certain embodiments, for each nucleus, all morphometric characteristics are defined with respect to the
segmentation of the nucleolus masses into a set of disjoint connected components. In certain
embodiments, this segmentation is obtained by nucleolar image thresholding, which means that a pixel is
considered to be part of the nucleolus if its intensity lies above the threshold (advantageously obtained
with nucleolar specific staining or other nucleolar visualization methods or techniques). In certain
embodiments, for each characteristic, the segmentation threshold parameter is defined automatically so as
to maximize the separation between the distributions of the characteristics for control cells and for test
cells, such as cells having disrupted nucleolar morphology or architecture. In certain embodiments, the
segmentation threshold is a morphometric characteristic parameter, and might vary from one
morphometric characteristic to the other.
In certain embodiments, the area of support of the nucleolus is characterized. In certain embodiments, the
size and number of connected components obtained after thresholding with a so-called area segmentation
threshold τα. is considered or determined. In certain embodiments, AAlcc measures the area of the
largest connected component in the thresholded image. In certain embodiments, ANcc denotes the
number of connected components in the nucleus. In certain embodiments, the sharpness index AS
characterizes the sharpness of the intensity gradient along the frontier delimiting the nucleolar masses,
and measures the ratio of the nucleus pixels that respectively lie above two thresholds and ¾ , with
> ¾ ·
In certain embodiments, to characterize the shape and the texture of the nucleolus, only the largest
connected component obtained after segmentation is considered.
In certain embodiments, to quantify the nucleolus shape regularity, we a shape segmentation threshold T
s
is adopted. In certain embodiments, the shape of the largest connected component in the segmented image
is characterized. In certain embodiments, each characteristic describes the shape independently of its size.
In certain embodiments, the elongation shape factor SElcc, is defined as the square root of the ratio of the
two second order moments, λΐ and λ2, of the connected component c around its principal axes. In certain
embodiments, the elliptical regularity factor SRlcc, is defined as the ratio between the area of the
connected component, and the area of the smallest ellipse lying outside the connected component, and
having the same center, the same principal axes, and the same elongation than the connected component.
In certain embodiments, the concavity factor SClcc, is defined as the ratio between the area of the
connected component and the area of its convex hull.
In certain embodiments, to characterize the nucleolar texture pattern scalar metrics to reflect the
distribution of intensities inside one or more, preferably the largest connected component is considered.
In certain embodiments, the distribution of pixel intensities is determined, preferably following cell-wise
dynamic range normalization. In certain embodiments, the connected component is segmented based on a
texture segmentation threshold τ,. In certain embodiments, the texture histogram low tail index THlcc
measures the percentage of pixels that lie below some intensity threshold a , preferably while being
located inside the erosion of the connected component by a 3 x 3 pixels structuring element. An erosion
may in certain embodiments be applied to the shape to get rid of the low intensity pixels lying on the
border of the shape. In certain embodiments, the texture uplands index TUlcc is defined to be the number
of connected regions lying above a threshold β, while being inside the connected component. In certain
embodiments, the texture peaks index TPlcc is defined to be the number of local maxima in the connected
component. In certain embodiments, the texture valleys index TVlcc is defined to be the number of local
minima in the connected component. In certain embodiments, the texture local minimum TLMlcc is
defined as the intensity of the smallest local minimum in the connected component.
In certain embodiments, selection of the morphometric characteristics is based on the Fisher's criterion
introduced by the popular Linear Discriminant Analysis (22). In certain embodiments, those parameters
or characteristics are selected so as to maximize the separation between the features distributions that we
want to discriminate (see also Example 2). The skilled person will understand that alternative selection
criteria may be applied, and which equally maximize the separation between the features to be
discriminated. In certain embodiments, a discriminant feature or characteristic is one for
which the class-means are well separated, measured relative to the (sum of the) variances of the data
assigned to a particular class.
In certain embodiments, considering a feature, parameterized by a vector p lying in a parameter space P,
it is assumed that the feature distributions are known as a function of p, for the two classes of
observations that we want to best discriminate. The Fishers' optimization criterion indicates that the
vector p* that maximizes the separation between the class distributions is defined as:
[ ) - 2(ρ)]2
where µ ΐ (ρ), µ2(ρ) and σ ΐ (ρ), σ2(ρ) respectively denote the means and standard deviations of the
distributions of the feature of interest, measured with parameter p for the two classes. This Fisher's
criterion is equivalent to the Welch's adaptation of the t-test (23), widely used in image-based
morphometry (24).
In certain embodiments, the parameters/characteristics are selected so as to maximize the sum of the
separation measured between each pair of distributions extracted from control cells, and from test cells,
such as cells having a disrupted nucleolar morphology.
In certain embodiments, a discrepancy vector is defined so as to summarize how the morphometric
characteristic distributions associated to a set of nucleoli differ from their corresponding reference
distributions. In certain embodiments, for a given image feature, the discrepancy d is defined between a
test set and a reference set, preferably to be the ratio of the difference of the mean feature values on each
set to the sum of their variance, preferably according to the following formula:
. µ
d(i) = ( ) - (
with µ ( ) , µ Γ( ) and σ( ), or(i) denoting the means and standard deviations of the characteristic/feature;
with d preferably being a discrepancy vector component.
In certain embodiments, to quantify the nucleolar disruption level, an index of nucleolar disruption, or
iNo is defined
In certain embodiments the iNo is defined according to the following formula:
wherein N is the number of features; wherein a(i) is a weighing factor for the 1th feature, wherein
preferably 0 < a(i) < 1; and wherein d(i) is the discrepancy vector component for the 1th feature. In certain
embodiments, the iNo is the Ll-norm of the discrepancy vector (i.e. all a(i) are equal).
In certain embodiments, a lower dimensional representation of the data is obtained. In certain
embodiments, such representation may be obtained by Principal components analysis (PCA). In certain
embodiments, the first two principal components are considered. In certain embodiments, the PCA is
applied to the discrepancy vectors that capture the average trends associated with nucleolar morphology,
architecture, or integrity. In certain embodiments, the 3, preferably 4, more preferably 5 features that
have the largest Fisher's score, i.e. which best discriminates normal and altered nucleoli are considered.
In certain embodiments, those features are as listed in the first column of Table 7.
In certain embodiments, the methods as described herein are computer implemented methods, in
particular computer implemented methods for characterizing nucleolar morphology according to the
invention as described herein. Accordingly, in certain embodiments, the invention relates to a method
according to the invention as described herein executed on a computer. In related aspects, the invention
provides a computer-readable medium comprising computer-readable instructions which, when loaded on
the internal memory of a computer, cause the computer to execute a method according to the invention as
described herein. In a further aspect, the invention relates to a data-stream comprising instructions for
carrying out a method according to the invention as described herein. In a further aspect, the invention
relates to a computer configured for executing a method according to the invention as described herein. In
a further aspect, the invention relates to a data-carrier comprising computer-readable instructions for
carrying out a method according to the invention as described herein. In a further aspect, the invention
relates to a data-carrier comprising computer-readable instructions which, when loaded on the internal
memory of a computer, cause the computer to execute a method according to the invention as described
herein.
In an aspect, the invention relates to a method for predicting, diagnosing, prognosing, or determining
nucleolar disruption or integrity, comprising determining the protein and/or mRNA expression level of
one or more (ribosomal) protein. In certain embodiments, said method is an in vitro method, an in vivo,
method, or an ex vivo method. In certain embodiments, said method is not an in vivo method in a human
or animal.
In certain embodiments, said (ribosomal) protein is selected as one or more, such as two or more, such as
three or more, such as all comprised in of any of lists (a) to (pp):
(a) eL33, eS24, eL8, uS4, eS28, eS27, uS7, uS9, uS19, eL36, uSll, uS8, uL24, eL18, eL32, eS27L,
eL29, uL16, uS13, eL24, eL15, uSIO, eSlO, eL42, uLlO, eL13, eS31, uLll, eL40, uL3, eS19, uL6,
eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6, eL31, uS14, uL22, uL30, uL29, eL30,
uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(b) eL33, eL8, eS27, eL36, uL24, eL18, eL32, eL29, uL16, eL24, eL15, eL42, uLlO, eL13, uLll,
eL40, uL3, uL6, eL34, eL39, eL37, uL4, eL14, eL27, uL15, eL20, eL6, eL31, uL22, uL30, uL29,
eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(c) eL33, eL8, eL13, eS31, eL36, eSlO, eS19, uL6, eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15,
eL20, eL6, eL31, uS14, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5,
and uL18;
(d) eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, uL4, eL14, eL27, uL15, eL20, eL6, eL31, uL22,
uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(e) eL13, eS31, eL36, eSlO, eS19, uL6, eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6,
eL31, uS14, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(f eL13, eL36, uL6, eL34, eL39, eL37, uL4, eL14, eL27, uL15, eL20, eL6, eL31, uL22, uL30,
uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(g) eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uL18, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll,
eL18, uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14,
eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(h) eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, uL18, eL24, uL14, uL16, eL40, uLll, eL18,
uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20,
uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(i) eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18,
uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27,
uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(j) eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, eL24, uL14, uL16, eL40, uLll, eL18, uL3,
uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22,
uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(k) uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18, uL3, uL4, uSIO,
eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22,
uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(1) eL24, uL14, uL16, eL40, uLll, eL18, uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34,
eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43,
uL2, and uLl;
(m) eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29,
eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(n) eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30,
uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(o) eL33, eL8, eL13, eL34, eL39, eL14, uL22, uL13, eL38, eL21, uL2, anduLl;
(p) eL33, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL29, eL30, uL13,
eL38, eL19, eL21, eL43, uL2, and uLl;
(q) eSlO, eS19, uL6, eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6, eL31, uS14, uL22,
uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(r) eS19, uL6, eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6, eL31, uS14, uL22, uL30,
uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(s) uL6, eL34, eL39, eL37, uL4, eL14, eL27, uL15, eL20, eL6, eL31, uL22, uL30, uL29, eL30, uL13,
eL38, eL19, eL21, eL43, uL2, uLl, uL5, anduL18;
(t) eSlO, uL4, eL14, eS30, eL27, uL15, eL20, eL6, eL31, uS14, uL22, uL30, uL29, eL30, uL13, eL38,
eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(u) uL4, eL14, eL27, uL15, eL20, eL6, eL31, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21,
eL43, uL2, uLl, uL5, and uL18;
(v) eSlO, eL20, eL6, eL31, uS14, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl,
uL5, and uL18;
(w) eL20, eL6, eL31, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and
uL18;
(x) uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(y) uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, anduL18;
(z) uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, anduL18;
(aa) uL13, eL38, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(bb) eL38, eL19, eL21, eL43, uL2, uLl, uL5, anduL18;
(cc) eSlO, eL19, eL21, eL43, uL2, uLl, uL5, and uL18;
(dd) eL19, eL21, eL43, uL2, uLl, uL5, anduL18;
(ee) eSlO, eL21, eL43, uL2, uLl, uL5, anduL18;
(ff eL21, eL43, uL2, uLl, uL5, and uL18;
(gg) eSlO, eL43, uL2, uLl, uL5, anduL18;
(hh) eL43, uL2, uLl, uL5, and uL18;
(ii) uL2, uLl, uL5, and uL18;
(jj) uLl, uL5, and uL18;
(kk) uL5, anduL18;
(11) uL18;
(mm) uL5;
(nn) BXDC1 and RRS1, or any protein involved in ribosomal central protuberance formation;
(oo) any one or more ribosomal protein selected from the above lists, except uL24, uL14, eS7, eL8, eS6,
eS19, uSll, eL37, eS26, eS31, eS27L, uS12, anduSlO; or
(pp) any one or more ribosomal protein selected from the above lists, except uL5 and/or uL18.
In certain embodiments, said (ribosomal) protein is one or more, such as two or more, such as three or
more, such as all (ribosomal) protein of any of (a) to (pp) above. In certain embodiments, said use is an in
vitro method, an in vivo, method, or an ex vivo method. In certain embodiments, said method is not an in
vivo method in a human or animal.
In a related aspect, the invention provides in the use of means for detecting the mRNA and/or protein
expression level of one or more, such as two or more, such as three or more, such as all (ribosomal)
protein for predicting, diagnosing, prognosing, or determining nucleolar disruption or integrity. In certain
embodiments, such use involves the use of means for detecting the mRNA and/or protein expression level
of any one or more, such as two or more, such as three or more, such as all (ribosomal) protein of any of
(a) to (pp) above. Means for detecting mRNA or protein expression are known in the art, and include by
means of further guidance, and without limitation primers, probes, and antibodies. In certain
embodiments, said use is an in vitro use, an in vivo use, or an ex vivo use. In certain embodiments, said
use is not an in vivo use in a human or animal.
By extension, in an aspect, the invention relates to a method for predicting, diagnosing, prognosing, or
determining a disease or disorder characterized by or associated with nucleolar disruption or integrity,
comprising determining the protein and/or mRNA expression level of one or more, such as two or more,
such as three or more, such as all (ribosomal) protein. In certain embodiments, said (ribosomal) protein is
one or more, such as two or more, such as three or more, such as all (ribosomal) protein of any of (a) to
(pp) above. In certain embodiments, said method is an in vitro method, an in vivo method, or an ex vivo
method. In certain embodiments, said method is not an in vivo method in a human or animal.
In a related aspect, the invention provides in the use of means for detecting the mRNA and/or protein
expression level, such as an inducer or inhibitor of mRNA and/or protein expression, of one or more, such
as two or more, such as three or more, such as all (ribosomal) protein for predicting, diagnosing,
prognosing, or determining a disease or disorder characterized by or associated with nucleolar disruption
or integrity nucleolar disruption or integrity. In certain embodiments, such use involves the use of means
for detecting the mRNA and/or protein expression level of any one or more, such as two or more, such as
three or more, such as all (ribosomal) protein of any of (a) to (pp) above. In certain embodiments, such
disease or disorder is cancer/tumor/malignancy/proliferative disease or disorder (or pre-cancerous/pre-
neoplastic/pre-malignant disorders or stages, such as hyperplasia, dysplasia, or metaplasia), autoimmune
disease, viral infection, neurodegenerative disorder, or ribosomopathy (such as cancer predisposition,
skeletal problems, or hematological problems). In certain embodiments, said use is an in vitro use, an in
vivo use, or an ex vivo use. In certain embodiments, said use is not an in vivo use in a human or animal.
In an aspect, the invention relates to a method for treating, alleviating or improving a disease or disorder
characterized by or associated with nucleolar disruption or integrity, comprising (specifically) decreasing
or increasing the mRNA or protein level or activity of one or more, such as two or more, such as three or
more, such as all (ribosomal) protein, such as with an inducer or inhibitor of mRNA and/or protein
expression. In certain embodiments, said (ribosomal) protein is one or more, such as two or more, such as
three or more, such as all (ribosomal) protein of any of (a) to (pp) above. In certain embodiments, such
disease or disorder is cancer/tumor/malignancy/proliferative disease or disorder (or pre-cancerous/pre-
neoplastic/pre-malignant disorders or stages, such as hyperplasia, dysplasia, or metaplasia), autoimmune
disease, viral infection, neurodegenerative disorder, or ribosomopathy (such as cancer predisposition,
skeletal problems, or hematological problems). In certain embodiments, said use is an in vitro method, an
in vivo method, or an ex vivo method. In certain embodiments, said method is not an in vivo method in a
human or animal. In certain embodiments, such method involves administering a therapeutically effective
amount of said means for increasing or decreasing expression levels or activity.
In an aspect, the invention relates to means for (specifically) increasing or decreasing the mRNA and/or
protein level or activity, such as an inducer or inhibitor of mRNA and/or protein expression, of a
(ribosomal) protein for use in treating, alleviating, or improving a disease or disorder characterized by or
associated with nucleolar disruption or integrity. In certain embodiments, said (ribosomal) protein is one
or more, such as two or more, such as three or more, such as all (ribosomal) protein of any of (a)
to (pp) above. In certain embodiments, such disease or disorder is cancer/tumor/malignancy/proliferative
disease or disorder (or pre-cancerous/pre-neoplastic/pre-malignant disorders or stages, such as
hyperplasia, dysplasia, or metaplasia), autoimmune disease, viral infection, neurodegenerative disorder,
or ribosomopathy (such as cancer predisposition, skeletal problems, or hematological problems).
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity of a (ribosomal) protein for the manufacture of a medicament for
treating, alleviating, or improving a disease or disorder characterized by or associated with nucleolar
disruption or integrity. In certain embodiments, said (ribosomal) protein is one or more, such as two or
more, such as three or more, such as all (ribosomal) protein of any of (a) to (pp) above. In certain
embodiments, such disease or disorder is cancer/tumor/malignancy/proliferative disease or disorder (or
pre-cancerous/pre-neoplastic/pre-malignant disorders or stages, such as hyperplasia, dysplasia, or
metaplasia), autoimmune disease, viral infection, neurodegenerative disorder, or ribosomopathy (such as
cancer predisposition, skeletal problems, or hematological problems).
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity of a (ribosomal) protein for treating, alleviating, or improving a
disease or disorder characterized by or associated with nucleolar disruption or integrity. In certain
embodiments, said (ribosomal) protein is one or more, such as two or more, such as three or more, such as
all (ribosomal) protein of any of (a) to (pp) above. In certain embodiments, such disease or disorder is
cancer/tumor/malignancy/proliferative disease or disorder (or pre-cancerous/pre-neoplastic/pre-malignant
disorders or stages, such as hyperplasia, dysplasia, or metaplasia), autoimmune disease, viral infection,
neurodegenerative disorder, or ribosomopathy (such as cancer predisposition, skeletal problems, or
hematological problems). In certain embodiments, said use is an in vitro use, an in vivo use, or an ex vivo
use. In certain embodiments, said use is not an in vivo use in a human or animal.
In an aspect, the invention relates to a method for modifying or altering nucleolar morphology,
architecture, or integrity, comprising (specifically) decreasing or increasing the mRNA or protein level or
activity, such as with and inducer or inhibitor of mRNA and/or protein expression, of one or more, such
as two or more, such as three or more, such as all (ribosomal) protein. In certain embodiments, said
(ribosomal) protein is one or more, such as two or more, such as three or more, such as all (ribosomal)
protein of any of (a) to (pp) above. In certain embodiments, said method is an in vitro method, an in vivo,
method, or an ex vivo method. In certain embodiments, said method is not an in vivo method in a human
or animal. In certain embodiments, said use is an in vitro method, an in vivo, method, or an ex vivo
method. In certain embodiments, said method is not an in vivo method in a human or animal.
In an aspect, the invention relates to means for (specifically) increasing or decreasing the mRNA and/or
protein level or activity, such as an inducer or inhibitor of mRNA and/or protein expression, of a
(ribosomal) protein for use in modifying or altering nucleolar morphology, architecture, or integrity,
comprising (specifically) decreasing or increasing the mRNA or protein level or activity of one or more,
such as two or more, such as three or more, such as all (ribosomal) protein. In certain embodiments, said
(ribosomal) protein is one or more, such as two or more, such as three or more, such as all (ribosomal)
protein of any of (a) to (pp) above.
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity, such as an inducer or inhibitor of mRNA and/or protein
expression, of a (ribosomal) protein for the manufacture of a medicament for modifying or altering
nucleolar morphology, architecture, or integrity. In certain embodiments, said (ribosomal) protein is one
or more, such as two or more, such as three or more, such as all (ribosomal) protein of any of (a) to (pp)
above.
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity, such as an inducer or inhibitor of mRNA and/or protein
expression, of a (ribosomal) protein for use in modifying or altering nucleolar morphology, architecture,
or integrity, comprising (specifically) decreasing or increasing the mRNA or protein level or activity of
one or more, such as two or more, such as three or more, such as all (ribosomal) protein. In certain
embodiments, said (ribosomal) protein is one or more, such as two or more, such as three or more, such as
all (ribosomal) protein of any of (a) to (pp) above. In certain embodiments, said use is an in vitro method,
an in vivo, method, or an ex vivo method. In certain embodiments, said method is not an in vivo method
in a human or animal.
In an aspect, the invention relates to a method for increasing or decreasing the protein level or activity of
p53 in a cell, comprising respectively decreasing or increasing the mRNA or protein level or activity,
such as with inducer or inhibitor of mRNA and/or protein expression, of one or more, such as two or
more, such as three or more, such as all ribosomal proteins selected as one or more, such as two or more,
such as three or more, such as all comprised in of any of lists (1) to (9):
1. eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uL18, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll,
eL18, uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14,
eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
2. eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, uL18, eL24, uL14, uL16, eL40, uLll, eL18,
uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20,
uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
3. eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18,
uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27,
uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
4. eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, eL24, uL14, uL16, eL40, uLll, eL18, uL3, uL4,
eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30,
uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
5. uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18, uL3, uL4,
uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20,
uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
6. eL24, uL14, uL16, eL40, uLll, eL18, uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34,
eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2,
and uLl;
7. eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29,
eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
8. eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30,
uL13, eL38, eL19, eL21, eL43, uL2, anduLl;
9. eL33, eL8, eL13, eL34, eL39, eL14, uL22, uL13, eL38, eL21, uL2, anduLl;
In certain embodiments, said method is an in vitro method, an in vivo, method, or an ex vivo method. In
certain embodiments, said method is not an in vivo method in a human or animal.
In an aspect, the invention relates to means for (specifically) increasing or decreasing the mRNA and/or
protein level or activity, such as an inducer or inhibitor of mRNA and/or protein expression, of a
(ribosomal) protein for use in decreasing or increasing respectively the protein level or activity of p53. In
certain embodiments, said (ribosomal) protein is one or more, such as two or more, such as three or more,
such as all (ribosomal) protein of (1) to (9) above.
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity, such as an inducer or inhibitor of mRNA and/or protein
expression, of a (ribosomal) protein for the manufacture of a medicament for decreasing or increasing
respectively the p53 protein level or activity. In certain embodiments, said (ribosomal) protein is one or
more, such as two or more, such as three or more, such as all (ribosomal) protein of (1) to (9) above.
In an aspect, the invention relates to the use of means for (specifically) increasing or decreasing the
mRNA and/or protein level or activity, such as an inducer or inhibitor of mRNA and/or protein
expression, of a (ribosomal) protein for decreasing or increasing respectively the p53 protein level or
activity. In certain embodiments, said (ribosomal) protein is one or more, such as two or more, such as
three or more, such as all (ribosomal) protein of (1) to (9) above. In certain embodiments, said use is an in
vitro use, an in vivo use, or an ex vivo use. In certain embodiments, said use is not an in vivo use in a
human or animal.
In certain embodiments, in the treatment methods and uses according to the invention as described herein
(including manipulation of nucleolar morphology and/or p53 protein level), if a decreased mRNA and/or
protein expression level of and one or more, such as two or more, such as three or more, such as all of the
(ribosomal) proteins of (pp) above is detected or determined, said treatment method or use may involve
decreasing or increasing the mRNA and/or protein level or activity of uL5 and/or uL18.
In an aspect, the invention relates to the use of any of the methods according to the invention as described
herein for identifying compounds affecting or altering nucleolar morphology, architecture, integrity, or
disruption or for identifying compounds affecting or altering (increasing or decreasing) p53 mRNA or
protein expression level, activity, stability and/or steady state levels. In certain embodiments, said
use is an in vitro use, an in vivo use, or an ex vivo use. In certain embodiments, said use is not an in vivo
use in a human or animal.
In an aspect, the invention relates to a screening method for identifying compounds affecting or altering
nucleolar morphology, architecture, integrity, or disruption or for identifying compounds affecting or
altering (increasing or decreasing) p53 mRNA or protein expression level, activity, stability and/or steady
state levels, with any of the methods according to the invention as described herein. In certain
embodiments, said method is an in vitro method, an in vivo method, or an ex vivo method. In certain
embodiments, said method is not an in vivo method in a human or animal.
In any of these methods, the detection or induction or decrease of the recited (ribosomal) proteins may be
done on (isolated) cells, in vitro, ex vivo, or in vivo in cells, tissues or organisms.
Methods for increasing or decreasing gene or protein expression or affecting protein stability are known
in the art. Such methods include but are not limited to for instance (conditional or inducible) knock-out,
(conditional or inducible) knock-down (e.g. siRNA), use of neutralizing compounds (e.g. small
molecules, antibodies, etc.), (conditional or inducible) overexpression, transcriptional or translational
activation, etc. Standard reference works setting forth the general principles of recombinant DNA
technology include Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Current Protocols in Molecular
Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1996 (with periodic
updates) ("Ausubel et al. 1996"); Innis et al., PCR Protocols: A Guide to Methods and Applications,
Academic Press: San Diego, 1990. General principles of microbiology are set forth, for example, in
Davis, B. D. et al., Microbiology, 3rd edition, Harper & Row, publishers, Philadelphia, Pa. (1980).
Except when explicitly noted, "subject" or "patient" are used interchangeably and refer to animals or
humans. Animals are preferably vertebrates, more preferably mammals such as veterinary animals, horse,
rabbit, mouse, rat, pig, sheep, cow or dog, etc.. The term subject specifically includes human patients.
The terms "diagnosing" or "diagnosis" generally refer to the process or act of recognising, deciding on or
concluding on a disease or condition in a subject on the basis of symptoms and signs and/or from results
of various diagnostic procedures (such as, for example, from knowing the presence, absence and/or
quantity of one or more biomarkers characteristic of the diagnosed disease or condition).
The terms "prognosticating" or "prognosis" generally refer to an anticipation on the progression of a
disease or condition and the prospect (e.g., the probability, duration, and/or extent) of recovery.
A good prognosis of cancer may generally encompass anticipation of a satisfactory partial or complete
recovery from cancer, preferably within an acceptable time period. A good prognosis of cancer may more
commonly encompass anticipation of not further worsening or aggravating of the heart failure condition,
preferably within a given time period.
A poor prognosis of cancer may generally encompass anticipation of a substandard recovery and/or
unsatisfactorily slow recovery, or to substantially no recovery or even further worsening of cancer.
The terms "sample" or "biological sample" as used herein include any biological specimen obtained
from a subject. Samples may include, without limitation, whole blood, plasma, serum, red blood cells,
white blood cells (e.g., peripheral blood mononuclear cells), saliva, urine, stool (i.e., faeces), tears, sweat,
sebum, nipple aspirate, ductal lavage, tumour exudates, synovial fluid, cerebrospinal fluid, lymph, fine
needle aspirate, amniotic fluid, any other bodily fluid, cell lysates, cellular secretion products,
inflammation fluid, semen and vaginal secretions. Samples may also include tissue samples and biopsies,
tissue homogenates and the like.
The one or more nucleolar markers in the form of proteins, polypeptides, peptides, nucleic acids, or
mRNA molecules are "measured" in a sample when the presence or absence and/or quantity of said
marker is detected or determined in the sample, preferably substantially to the exclusion of other
molecules and analytes.
The terms "quantity", "amount" and "level" are synonymous and generally well-understood in the art. The
terms as used herein may particularly refer to an absolute quantification of a marker in a sample, or to a
relative quantification of a marker in a sample, i.e., relative to another value such as relative to a reference
value as taught herein, or to a range of values indicating a base-line expression of the marker. These
values or ranges can be obtained from a single patient or from a group of patients.
An absolute quantity of a marker in a sample may be advantageously expressed as weight or as molar
amount, or more commonly as a concentration, e.g., weight per volume or mol per volume.
A relative quantity of a marker in a sample may be advantageously expressed as an increase or decrease
or as a fold-increase or fold-decrease relative to said another value, such as relative to a reference value
from a certain type of tumour or a healthy sample.
The term "treating" as used herein includes treating any one or more of the diseases or disorders as
described herein. Treatment of for instance cancer means administration of a medicament in the form of a
compound or pharmaceutical composition of the invention with the result that cancer is stabilized,
reduced or the patient is cured.
As used herein, the terms "treat" or "treatment" refer to both therapeutic treatment and prophylactic or
preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological
change or disorder, such as the development or spread of disease, e.g., cancer. Beneficial or desired
clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease,
stabilised (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or
palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
"Treatment" can also mean prolonging survival as compared to expected survival if not receiving
treatment.
As used herein, a phrase such as "a subject in need of treatment" includes subjects, such as mammalian
subjects, that would benefit from treatment of a given disease or disorder, such as, e.g., cancer.
Such subjects will typically include, without limitation, those that have been diagnosed with the
condition, preferably a disease or disorder as defined herein elsewhere, e.g., cancer, those prone to have
or develop the said condition and/or those in whom the condition is to be prevented.
The term "therapeutically effective amount" refers to an amount of a compound or pharmaceutical
composition of the invention effective to treat a disease or disorder in a subject, i.e., to obtain a desired
local or systemic effect and performance. By means of example and not limitation, in the case of
proliferative disease, e.g., cancer, therapeutically effective amount of a drug may reduce the number of
cancer cells; reduce the tumour size; inhibit (i.e., slow to some extent and preferably stop) cancer cell
infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumour
metastasis; inhibit, to some extent, tumour growth; enhance efficacy of another cancer therapy; and/or
relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug
may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer
therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or
determining the response rate (RR). The term thus refers to the quantity of compound or pharmaceutical
composition that elicits the biological or medicinal response in a tissue, system, animal, or human that is
being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of
the symptoms of the cancer being treated. In particular, these terms refer to the quantity of compound or
pharmaceutical composition according to the invention which is necessary to prevent, cure, ameliorate, or
at least minimize the clinical impairment, symptoms, or complications associated with cancer in either a
single or multiple doses.
The treatment methods and uses according to the invention as described herein may in certain
embodiments involve the administration of a composition comprising the means for inducing or reducing
protein or mRNA expression level or activity. In certain embodiments, such composition is a
pharmaceutical composition. In certain embodiments, such composition further comprises one or more
pharmaceutically acceptable excipients.
The term "pharmaceutically acceptable" as used herein is consistent with the art and means compatible
with the other ingredients of a pharmaceutical composition and not deleterious to the recipient thereof.
The term "pharmaceutically acceptable salts" as used herein means an inorganic acid addition salt such as
hydrochloride, sulfate, and phosphate, or an organic acid addition salt such as acetate, maleate, fumarate,
tartrate, and citrate. Examples of pharmaceutically acceptable metal salts are alkali metal salts such as
sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt,
aluminum salt, and zinc salt. Examples of pharmaceutically acceptable ammonium salts are ammonium
salt and tetramethylammonium salt. Examples of pharmaceutically acceptable organic amine addition
salts are salts with morpholine and piperidine. Examples of pharmaceutically acceptable amino acid
addition salts are salts with lysine, glycine, and phenylalanine.
Examples
Example 1: Materials and methods
Nucleolar screens
The nucleolar screens were performed on an automated high throughput platform. For each r-protein,
three different siRNAs were used, and for each siRNA, 2,000 cells imaged. For consistency, the entire
screen was duplicated. The efficiency of siRNA-mediated depletion was assessed in a random shotgun
RTqPCR assay. A calibration set consisting of four control proteins whose depletion, we established,
affects strongly nucleolar structure was used (Supplementary Fig. 1).
Cell lines
The cell lines used in this study are listed in Table 1. All cell lines were cultured at 37°C under 5% C02.
Culture media were supplemented with 10% fetal bovine serum (FBS; Sigma) and 1% penicillin-
streptomycin (Pen-Strep, Gibco). For consistency, the experiments were performed on cells grown for 10
to 15 passages. The nucleolar screens were conducted in cervical cancer (HeLa) cells stably expressing
FBL in fusion with GFP (FIB364). All cell lines were purchased from the ATCC repository and regularly
tested for contamination with the LookOut mycoplasma PCR detection kit (Sigma-Aldrich, MP0035).
Table 1
siRNA depletion
The FIB364 cell line was transfected with either of 3 distinct siRNAs targeting each r-protein according
to the protocol described below (Table 2 for siRNA sequences). The entire screening procedure was
duplicated. Depletions were performed in 96-well plates (Porvair Sciences). A transfection reagent mix
(0.125 µΐ of Interferin and 20 µΐ of Optimem) was added to each plate well and left to set for 10 min at
RT. siRNA (10 µΐ of 100 nM stock) were added to this mix and left to set for another 30 min at RT. Cells
(70 µΐ of 100,000 cells/ml) were added to each well and the plates were incubated for 3 days. For each
individual plate, a set of 7 wells was used for negative and positive controls. Our calibration set consists
of mock-treated cell (cells with the transfection reagent mix only) and cells treated with a non-targeting
siRNA (Scramble, SCR), or with siRNA specific to GFP, fibrillarin (FBL), nucleophosmin (NPM),
nucleolin (NCL), or TIFIA. Cells were fixed in 2% formaldehyde, washed in PBS, incubated 10 min in
the presence of DAPI (1:20,000 of 5 mg/ml in PBS, Sigma), washed again and stored in PBS before
imaging. The depletion of the central protuberance assembly factors RRS1 and BXDC1 were performed
according to the same protocol.
Table 2
Ribosomal proteins (RPs)
New GenBank
Gene nomenclat accession siRNA siRNA siRNA sequence
name ure number number ID (5' to 3') Source
CUCCUGGAACC Ambion, Life
RpSA uS2 XM_939738 # 1 s60434 UUCACUAAtt Technologies
GCACCAAUCU Ambion, Life
#2 s51977 UGACUUCCAtt Technologies
GCAUCUAUAU Ambion, Life
#3 s51978 CAUAAAUCUtt Technologies
CCAAGUCUCCC Ambion, Life
RpS2 uS5 NM_002952 # 1 s12252 UAUCAGGAtt Technologies
UCUCCGCACCU Ambion, Life
#2 s12253 GUGCCUAAtt Technologies
CCUAAGAAGC Ambion, Life
#3 s12254 UGCUCAUGAtt Technologies
UGACUGCUGU Ambion, Life
RpS3 uS3 NM_001005 # 1 s12255 AGUUCAGAAtt Technologies
GCGGAGACCC Ambion, Life
#2 s12256 UGUUAACUAtt Technologies
AAGCUGAACU Ambion, Life
#3 s12257 GAAUGAGUUtt Technologies
GCAACAAUCA Ambion, Life
RpS3A eSl NM_001006 # 1 sl2258 GAUACGGAAtt Technologies
AAUUCAAGCU Ambion, Life
#2 s12259 GAUUACUGAtt Technologies
AGAUUGGUAU Ambion, Life
#3 s12260 GAUGUGAAAtt Technologies
GCGGUUCAUU Ambion, Life
RpS4X eS4 NM_001007 # 1 s12261 AAAAUCGAUtt Technologies
GCAUGCAGCG Ambion, Life
#2 s12262 GUUCAUUAAtt Technologies
AGACUUAAGU Ambion, Life
#3 s12263 AUGCCCUGAtt Technologies
CCGGAACAUU Ambion, Life
RpS5 uS7 NM_001009 # 1 s12267 AAGACCAUUtt Technologies
ACAUUGCAGU Ambion, Life
#2 sl2268 GAAGGAGAAtt Technologies
GCAUGCCUUC Ambion, Life
#3 s12269 GAGAUCAUAtt Technologies
CCUUAAAUAA Ambion, Life
RpS6 eS6 NM_001010 # 1 s12270 AGAAGGUAAtt Technologies
GGAACAAAUU Ambion, Life
#2 s12271 GCGAAGAGAtt Technologies
CAGCGUACCA Ambion, Life
#3 s12272 AGAAAAAUAtt Technologies
CAUAAUCUUU Ambion, Life
RpS7 eS7 NM_001011 # 1 sl2288 GUUCCCGUUtt Technologies
GAGUUUCAAU Ambion, Life
#2 sl2289 UGUAAACAAtt Technologies
GUACGCGAAU Ambion, Life
#3 s12290 UGGAGAAAAtt Technologies
GCUAUGUGCU Ambion, Life
RpS8 eS8 NM__001012 # 1 s12291 AGAGGGCAAtt Technologies
GAAAUAUGAU Ambion, Life
#2 s12292 GAAAGGAAAtt Technologies
AGAGUGUUGU Ambion, Life
#3 s12293 ACUCGUAAAtt Technologies
AGAUGAAGCU Ambion, Life
RpS9 uS4 NM__001013 # 1 s12294 GGAUUACAUtt Technologies
AGAUAGAGGA Ambion, Life
#2 s12295 UUUCUUAGAtt Technologies
AGCUGAAGCU Ambion, Life
#3 s12296 GAUCGGCGAtt Technologies
GCAACCGAAU Ambion, Life
RpSlO eSlO NM__001014 # 1 s12297 UCCAGUUUAtt Technologies
CGACCUGCGA Ambion, Life
#2 s12298 GACUCACAAtt Technologies
CAUUUCUACU Ambion, Life
#3 s12299 GGUACCUUAtt Technologies
AGAACAUGUC Ambion, Life
RpSll uS17 NM__001015 # 1 s12300 UGUACACCUtt Technologies
CUACAUCCGCA Ambion, Life
#2 S200170 AGUACAACtt Technologies
CCAGAUCGGU Ambion, Life
#3 S200171 GACAUCGUCtt Technologies
CCUUUGUGCU Ambion, Life
RpS12 eS12 NM__001016 # 1 s52989 GAACACCAAtt Technologies
GGCCUUUGUA Ambion, Life
#2 sl94763 AAAUUGACAtt Technologies
ACUGUGAUGA Ambion, Life
#3 si 94764 GCCUAUGUAtt Technologies
GAAAGGAUAA Ambion, Life
RpS13 uS15 NM__001017 # 1 s12304 GGAUGCUAAtt Technologies
GGCCUUACUCC Ambion, Life
#2 s12305 UUCACAGAtt Technologies
GCUCGAUAUU Ambion, Life
#3 sl2306 AUAAGACCAtt Technologies
NM__001025 AGACCGAGAU Ambion, Life
RpS14 uSll 070 # 1 s12307 GAAUCCUCAtt Technologies
AGGUAAAGGC Ambion, Life
#2 sl2308 AGACCGAGAtt Technologies
CAUCCUUCAA Ambion, Life
#3 s12309 UGACACUUUtt Technologies
CCUACAAGCCC Ambion, Life
RpS15 uS19 NM__001018 # 1 sl2310 GUAAAGCAtt Technologies
CUUCAUCCCUC Ambion, Life
#2 si 94765 UCAAGUAAtt Technologies
GCAUGGUGGG Ambion, Life
#3 sl94766 CGUCUACAAtt Technologies
RpS15 CCAAAGUCAU Ambion, Life
A uS8 NM__001019 # 1 sl2311 CGUCCGGUUtt Technologies
AGAUUUGACG Ambion, Life
#2 sl2312 UGCAACUCAtt Technologies
GAGUAUCAAC Ambion, Life
#3 sl2313 AAUGCCGAAtt Technologies
RpS16 uS9 NM__001020 # 1 sl2314 AGAUUUAUGC Ambion, Life
UAUCCGUCAtt Technologies
GCAAUGGUCU Ambion, Life
#2 sl2315 CAUCAAGGUtt Technologies
GGAGCGAUUU Ambion, Life
#3 sl2316 GCUGGUGUAtt Technologies
GCCCGGGUCA Ambion, Life
RpS17 eS17 NM__001021 # 1 sl2317 UCAUAGAAAtt Technologies
GGAGAUUAUU Ambion, Life
#2 sl2318 GAAGUAGAUtt Technologies
GGAUCAGGAG Ambion, Life
#3 sl2319 AUUAUUGAAtt Technologies
UGCGAGUACU Ambion, Life
RpS18 uS13 NM_
.
022551 # 1 s12320 CAACACCAAtt Technologies
UGAUCACCAU Ambion, Life
#2 sl2321 UAUGCAGAAtt Technologies
CGAUGGGCGG Ambion, Life
#3 s12322 CGGAAAAUAtt Technologies
GCCGCAAACU Ambion, Life
RpS19 eS19 NM__001022 # 1 sl2323 GACACCUCAtt Technologies
AAACCAUGCU Ambion, Life
#2 si 94767 GGGUUAAUAtt Technologies
AGCUGGCCAA Ambion, Life
#3 sl94768 GCACAAAGAtt Technologies
GGACCAGUUC Ambion, Life
RpS20 uSIO NM_
.
001023 # 1 s12324 GAAUGCCUAtt Technologies
GCCGCAACGU Ambion, Life
#2 s12325 AAAAUCCUUtt Technologies
CUAACAAGCC Ambion, Life
#3 sl2326 GCAACGUAAtt Technologies
AGUUUAAAAC Ambion, Life
RpS21 eS21 NM_ 001024 # 1 s12327 UUAUGCUAUtt Technologies
GUAGGAUGGG Ambion, Life
#2 S226974 UGAGUCAGAtt Technologies
GCAUCAUCGG Ambion, Life
#3 si 94769 UGCCAAGGAtt Technologies
CCAAUGACGG Ambion, Life
RpS23 uS12 NM_
.
001025 # 1 sl2328 UUGCUUGAAtt Technologies
GAAGCUCCGU Ambion, Life
#2 s12329 AGUCACCGAtt Technologies
UGACGGUUGC Ambion, Life
#3 sl2330 UUGAACUUUtt Technologies
CCGACUACUUC Ambion, Life
RpS24 eS24 NM_
.
001026 # 1 sl2331 AGAGGAAAtt Technologies
AGACAGAAAU Ambion, Life
#2 sl2332 UCGGGAAAAtt Technologies
CCUGGAUUAU Ambion, Life
#3 sl2333 GCAAAGAAAtt Technologies
GCACAGAGCU Ambion, Life
RpS25 eS25 NM_
.
001028 # 1 sl2334 CAAGUAAUUtt Technologies
GGAGCUCCUU Ambion, Life
#2 sl2335 AGUAAAGGAtt Technologies
GGAAGUUCCC Ambion, Life
#3 sl2336 AACUAUAAAtt Technologies
NM_
.
001093 ACAGCAAAGU Ambion, Life
RpS26 eS26 731 # 1 s229467 AGUCAGGAAtt Technologies
CAAGCUGUAU Ambion, Life
#2 s53606 GUGAAGCUAtt Technologies
AUUCGUCAUU Ambion, Life
#3 s229468 CGAAACAUAtt Technologies
GGAGGAAAAG Ambion, Life
RpS27 eS27 NM_
.
001030 # 1 sl2337 CAAGGCUUAtt Technologies
AUGCACAAAC Ambion, Life
#2 sl2338 GGUAGUUUUtt Technologies
GGAGGAAGCA Ambion, Life
#3 si 94771 GCACUAAAAtt Technologies
RpS27 AAGUCCAAAU Ambion, Life
L eS27L NM_
.
015920 # 1 s27333 UCUUACUUUtt Technologies
AAAUGUCCAG Ambion, Life
#2 s27334 GUUGCUACAtt Technologies
UGUCCAGGUU Ambion, Life
#3 s27335 GCUACAAGAtt Technologies
RpS27 GUACUUUGUC Ambion, Life
A eS31 NM_
.
002954 # 1 s12340 UGACUACAAtt Technologies
GGACGUACUU Ambion, Life
#2 sl2341 UGUCUGACUtt Technologies
GAAGAAGUCU Ambion, Life
#3 s226976 UACACCACUtt Technologies
CCAUCAUCCGC Ambion, Life
RpS28 eS28 NM_
.
001031 # 1 s12342 AAUGUAAAtt Technologies
GCCGAUCCAUC Ambion, Life
#2 sl2343 AUCCGCAAtt Technologies
GCGUGGAAUU Ambion, Life
#3 S226977 CAUGGACGAtt Technologies
NM_
.
001030 GCACGGUCUG Ambion, Life
RpS29 uS14 001 # 1 S227039 AUCCGGAAAtt Technologies
CGUCAGUACG Ambion, Life
#2 si 94772 CGAAGGAUAtt Technologies
GGAAAUAUGG Ambion, Life
#3 sl96844 CCUCAAUAUtt Technologies
UGAGAGGUCA Ambion, Life
RpS30 eS30 NM_
.
001997 # 1 s5039 GACUCCUAAtt Technologies
CCAGAUCAAG Ambion, Life
#2 s5040 GCUCAUGUAtt Technologies
UUCUGGCUUU Ambion, Life
#3 si 94404 CUCUAAUAAtt Technologies
CAGGCUAUCU Ambion, Life
Rackl Rackl NM_
.
006098 # 1 s20340 GAACACGGUtt Technologies
CAAACACCUU Ambion, Life
#2 s20341 UACACGCUAtt Technologies
GGAUGAGACC Ambion, Life
#3 s20342 AACUAUGGAtt Technologies
GGCAUAAAUC Ambion, Life
RpL3 uL3 NM_
.
000967 # 1 sl2142 UAAGAAGAAtt Technologies
ACGGCAAGCU Ambion, Life
#2 sl2143 GAUCAAGAAtt Technologies
GACUAUGACC Ambion, Life
#3 sl2144 UAUCUGACAtt Technologies
GACCAGAUAU Ambion, Life
RpL4 uL4 NM_
.
000968 # 1 sl2148 UGUGAACUUtt Technologies
#2 sl2149 GGCCGAAUGU Ambion, Life
UUGCACCAAtt Technologies
CCGCUUCCCUC Ambion, Life
#3 sl2150 AAGAGUAAtt Technologies
GACGAGAGGG Ambion, Life
RpL5 uL18 NM_
.
000969 # 1 sl2151 UAAAACUGAtt Technologies
GGAGGAGAUG Ambion, Life
#2 sl2152 UAUAAGAAAtt Technologies
GAAGUACAUC Ambion, Life
#3 sl2153 GGAAGCACAtt Technologies
AGCGCAAGAU Ambion, Life
RpL6 eL6 NM_
.
000970 # 1 sl2154 UGAUCAGAAtt Technologies
CCAAAAUCGA Ambion, Life
#2 sl2155 UAUCAGCAAtt Technologies
CCCAAAACAUC Ambion, Life
#3 sl2156 UUACUGAUtt Technologies
CUCGAUCUCU Ambion, Life
RpL7 uL30 NM_
.
000971 # 1 s352 UGGUAAAUAtt Technologies
CACUAUCACA Ambion, Life
#2 s353 AGGAAUAUAtt Technologies
CGUCAAAUCU Ambion, Life
#3 s354 UCAAUGGAAtt Technologies
GGUGAACUCG Ambion, Life
RpL7A eL8 NM_ 000972 # 1 sl2157 GAAGACAAAtt Technologies
CAGCUGUCGU Ambion, Life
#2 sl2158 GAAGAAGCAtt Technologies
AGUACAGACC Ambion, Life
#3 sl2159 AGAGACAAAtt Technologies
GCCGAAUUGA Ambion, Life
RpL8 uL2 NM_
.
000973 # 1 sl2160 CAAACCCAUtt Technologies
CCAUGCCUGA Ambion, Life
#2 sl2161 GGGUACAAUtt Technologies
CGGGAUCCGU Ambion, Life
#3 sl2162 AUCGGUUUAtt Technologies
AUGUCGACAU Ambion, Life
RpL9 uL6 NM_
.
000661 # 1 sl2163 UACUCUGAAtt Technologies
GAAAGAUGAA Ambion, Life
#2 sl2164 UUAAUCCUUtt Technologies
CCAGAAAAUG Ambion, Life
#3 sl2165 UCGACAUUAtt Technologies
GAAACAGGUU Ambion, Life
RpLlO uL16 NM_
.
006013 # 1 sl2166 GACAACUCAtt Technologies
CUAUGUCUUU Ambion, Life
#2 sl2167 GUAUCUACAtt Technologies
CCCGAAUUUG Ambion, Life
#3 si 96275 UGCCAAUAAtt Technologies
RpLlO GUCCGGGCCU Ambion, Life
A uLl NM_
.
007104 # 1 s9421 UAUAUAUCAtt Technologies
CAGAGUCUCU Ambion, Life
#2 s9422 GAUCAAGCAtt Technologies
UGAAGAAGGU Ambion, Life
#3 s9423 GUUAUGUCUtt Technologies
GGUGCGGGAG Ambion, Life
RpLll uL5 NM_
.
000975 # 1 sl2168 UAUGAGUUAtt Technologies
CAACUUCUCA Ambion, Life
#2 sl2169 GAUACUGGAtt Technologies
GGAACUUCGC Ambion, Life
#3 sl2170 AUCCGCAAAtt Technologies
CCCAGUCAGU Ambion, Life
RpL12 uLll NM_
.
000976 # 1 si 94741 GGGCUGUAAtt Technologies
CCAGCCAGUU Ambion, Life
#2 si 94742 AAGCACAAAtt Technologies
AGCCCUCAAG Ambion, Life
#3 si 94743 GAACCACCAtt Technologies
GGAAGAGAAG Ambion, Life
RpL13 eL13 NM_
.
000977 # 1 sl2171 AAUUUCAAAtt Technologies
AGAAGAAUUU Ambion, Life
#2 sl2172 CAAAGCCUUtt Technologies
CGGCAUACGG Ambion, Life
#3 sl2173 GCAAAAAGAtt Technologies
RpL13 AGCUCAUGAG Ambion, Life
A uL13 NM_
.
012423 # 1 s58865 GCUACGGAAtt Technologies
GGUGUUUGAC Ambion, Life
#2 s23995 GGCAUCCCAtt Technologies
GGAAACAGGC Ambion, Life
#3 s23996 CGAGAAGAAtt Technologies
NM_
.
001034 GACAGAUUUU Ambion, Life
RpL14 eL14 996 # 1 sl7238 GAUCGUUUUtt Technologies
CCAGAAGUAU Ambion, Life
#2 sl7239 GUCCGACAAtt Technologies
AGAUCACCGCC Ambion, Life
#3 s17240 GCGAGUAAtt Technologies
CCUUUCAAGU Ambion, Life
RpL15 eL15 NM_
.
002948 # 1 sl2174 GUGAGCUUAtt Technologies
CCUUAAGAUU Ambion, Life
#2 sl2175 GGUAAGCUAtt Technologies
GGUGUAGACU Ambion, Life
#3 sl2176 UUUUAAGUUtt Technologies
CACGAAAUCA Ambion, Life
RpL17 uL22 NM_
.
000985 # 1 sl2177 UGCAAAUCAtt Technologies
CAAUCUUCGU Ambion, Life
#2 sl2178 GUUCACUUUtt Technologies
GCACAUGCUU Ambion, Life
#3 sl2179 AAAAACGCAtt Technologies
GGCUGUUGGU Ambion, Life
RpL18 eL18 NM_
.
000979 # 1 si 94744 CAAGUUAUAtt Technologies
AAACUAACCC Ambion, Life
#2 si 94745 UGGAUCCUAtt Technologies
CGGAUGAUCC Ambion, Life
#3 si 94746 GGAAGAUGAtt Technologies
RpL18 GUACUUUGUA Ambion, Life
A eL20 NM_
.
000980 # 1 sl2180 UCUCAGUUAtt Technologies
CCCACAACAUG Ambion, Life
#2 sl2181 UACCGGGAtt Technologies
ACUCCAUUCA Ambion, Life
#3 sl2182 GAUCAUGAAtt Technologies
AGACCAAGGA Ambion, Life
RpL19 eL19 NM_
.
000981 # 1 sl2183 AGCACGCAAtt Technologies
AGAAGAUACC Ambion, Life
#2 sl2184 GUGAAUCUAtt Technologies
#3 sl2185 GCUCAGAAGA Ambion, Life
UACCGUGAAtt Technologies
CACUCUAAGA Ambion, Life
RpL21 eL21 NM_
.
000982 # 1 sl2186 GCCGAGAUAtt Technologies
GGAAGAGUCU Ambion, Life
#2 sl2187 ACAAUGUUAtt Technologies
GGUGAUAUUG Ambion, Life
#3 sl2188 UAGACAUCAtt Technologies
GAGAGUUACG Ambion, Life
RpL22 eL22 NM_
.
000983 # 1 sl2189 AAUUACGUUtt Technologies
CAAAGAGAGU Ambion, Life
#2 sl2190 UACGAAUUAtt Technologies
GGUUGCGCGU Ambion, Life
#3 sl2191 AGUUGCUAAtt Technologies
GCAGGAGUCA Ambion, Life
RpL23 uL14 NM_
.
000978 # 1 sl7871 UAGUGAACAtt Technologies
CAAUAAAGGC Ambion, Life
#2 sl7872 GAGAUGAAAtt Technologies
CAACGAAAGU Ambion, Life
#3 sl7873 CAUACCGUAtt Technologies
RpL23 GAGUUAGUGU Ambion, Life
A uL23 NM_ 000984 # 1 sl2192 CCUAGGAAAtt Technologies
AGAGAUCUUU Ambion, Life
#2 sl2193 GUGACUAGAtt Technologies
CUGUUCUACU Ambion, Life
#3 sl2194 UAUCCUUUUtt Technologies
CGAGCAGUCA Ambion, Life
RpL24 eL24 NM_
.
000986 # 1 sl2198 AAUUCCAGAtt Technologies
AGAAACCUGA Ambion, Life
#2 sl2199 AGUUAGAAAtt Technologies
CUACAAAGGC Ambion, Life
#3 s12200 AGCACCUAAtt Technologies
CCACAUUCGA Ambion, Life
RpL26 uL24 NM_
.
000987 # 1 sl2201 AGGAAGAUUtt Technologies
GGUUGUACGU Ambion, Life
#2 s12202 GGACACUAUtt Technologies
GAAAUAUGUU Ambion, Life
#3 s12203 AUCUACAUUtt Technologies
GAGAGAUACA Ambion, Life
RpL27 eL27 NM_
.
000988 # 1 s12204 AGACAGGCAtt Technologies
ACAAAACUGU Ambion, Life
#2 s12205 CGUCAAUAAtt Technologies
AAACUGUCGU Ambion, Life
#3 s12206 CAAUAAGGAtt Technologies
RpL27 GGAUCAACUU Ambion, Life
A uL15 NM_
.
000990 # 1 sl2210 CGACAAAUAtt Technologies
GCCCAACUGUC Ambion, Life
#2 sl2211 AACCUUGAtt Technologies
CACUUAAAGA Ambion, Life
#3 sl2212 GGAACCAGAtt Technologies
CACCGUCUCUA Ambion, Life
RpL28 eL28 NM_
.
000991 # 1 sl2213 AAAUAAAAtt Technologies
GCACUGAGCCC Ambion, Life
#2 sl2214 AAUAACUUtt Technologies
UGAUCAAGAG Ambion, Life
#3 sl2215 GAAUAAGCAtt Technologies
CCUGUGCUAU Ambion, Life
RpL29 eL29 NM_
.
000992 # 1 sl2216 UUGUACAAAtt Technologies
CGAUCACAAA Ambion, Life
#2 sl2217 GAUACGAAUtt Technologies
GGAACAUGCG Ambion, Life
#3 si 94747 CUUUGCCAAtt Technologies
GGCUAUCAUU Ambion, Life
RpL30 eL30 NM_
.
000989 # 1 s12207 GAUCCAGGUtt Technologies
GGCUCCAACUC Ambion, Life
#2 s12208 GUUAUGAAtt Technologies
GGAAAUCUGA Ambion, Life
#3 s12209 AAUAGAGUAtt Technologies
CUCCAGAUGU Ambion, Life
RpL31 eL31 NM_
.
000993 # 1 sl2218 GCGCAUUGAtt Technologies
GGAAUGUGCC Ambion, Life
#2 si 94749 AUACCGAAUtt Technologies
CCAAAUAAGC Ambion, Life
#3 s231333 UAUAUACUUtt Technologies
UGGUUAUGGA Ambion, Life
RpL32 eL32 NM_ 000994 # 1 s12220 AGCAACAAAtt Technologies
GACUGGUACU Ambion, Life
#2 sl2221 CAGAAUUUAtt Technologies
ACAGGGUUCG Ambion, Life
#3 S227220 UAGAAGAUUtt Technologies
AUAGAAUUGU Ambion, Life
RpL34 eL34 NM_
.
000995 # 1 s12222 UUACCUUUAtt Technologies
AAAUCGUUGU Ambion, Life
#2 s12223 GAAAGUGUUtt Technologies
CAAUACAGCC Ambion, Life
#3 s12224 UCUAACAAAtt Technologies
CAAGCUCUCU Ambion, Life
RpL35 uL29 NM_
.
007209 # 1 s22151 AAGAUCCGAtt Technologies
GGAAAUCCAU Ambion, Life
#2 s22152 UGCCCGUGUtt Technologies
UAACCAGACU Ambion, Life
#3 s22153 CAGAAAGAAtt Technologies
RpL35 GUAUAUAAAG Ambion, Life
A eL33 NM_
.
000996 # 1 s12225 CAAAGAACAtt Technologies
ACAGAAUUCU Ambion, Life
#2 s12226 AUUUGGGCAtt Technologies
GAGAUGCGCU Ambion, Life
#3 s12227 UAUGUAUAUtt Technologies
CCCUCAAAUU Ambion, Life
RpL36 eL36 NM_
.
015414 # 1 s24653 UAUCAAGAAtt Technologies
AAACGGGCCC Ambion, Life
#2 s24654 UCAAAUUUAtt Technologies
GCGCCAUGGA Ambion, Life
#3 s226046 GUUACUGAAtt Technologies
RpL36 AGUGUCAUCU Ambion, Life
A elA2 NM_
.
021029 # 1 sl99106 UUUAUUAUGtt Technologies
GACUUUCUGU Ambion, Life
#2 s231826 AAGAAGUGUtt Technologies
CUAAGCCGAU Ambion, Life
#3 s231827 UUUCCGGAAtt Technologies
RpL37 eL37 NM_
.
000997 # 1 s12230 GAACAACACC Ambion, Life
UAAACCCAAtt Technologies
GGUCGAAUGA Ambion, Life
#2 s12231 GGCACCUAAtt Technologies
GCUAAAAGAC Ambion, Life
#3 s12232 GAAAUACCAtt Technologies
RpL37 CACUUCCGCUG Ambion, Life
A elA3 NM_000998 # 1 sl2233 UCACGGUAtt Technologies
CGCCAAGUAC Ambion, Life
#2 si 94751 ACUUGCUCUtt Technologies
GGUAAAGUCC Ambion, Life
#3 si 94752 GCCAUCAGAtt Technologies
AGGACAACGU Ambion, Life
RpL38 eL38 NM_000999 # 1 s12234 GAAGUUUAAtt Technologies
GGACAACGUG Ambion, Life
#2 S194753 AAGUUUAAAtt Technologies
CCGACGAAAG Ambion, Life
#3 si 94754 GAUGCCAAAtt Technologies
UCACGAUCAU Ambion, Life
RpL39 eL39 NM_001000 # 1 s12235 GUUACCAUAtt Technologies
GGAGAUUUCG Ambion, Life
#2 si 94755 ACGUGUUUUtt Technologies
CCACUAUCUG Ambion, Life
#3 sl94756 GAGAUUUCGtt Technologies
NM_001033 AGACAAGGAG Ambion, Life
RplA elA 930 # 1 sl4556 GGUAUCCCAtt Technologies
AAAUACAACU Ambion, Life
#2 sl4557 GCGACAAGAtt Technologies
GUCUGAUAUU Ambion, Life
#3 sl4558 UGCCGGCAAtt Technologies
NM_001035 CAAUGGAUCU Ambion, Life
RpIAl elAl 267 # 1 sl2236 AGAACUUCAtt Technologies
CCACCUUGCUC Ambion, Life
#2 s12237 AUAAACAAtt Technologies
GUAACAACCA Ambion, Life
#3 sl2238 UAUAAUAAAtt Technologies
AGAUCAUCCA Ambion, Life
P0 uLlO NM_001002 # 1 s226965 ACUAUUGGAtt Technologies
CGAGGGCACC Ambion, Life
#2 s226966 UGGAAAACAtt Technologies
GUUUCAUUGU Ambion, Life
#3 s785 GGGAGCAGAtt Technologies
GCACGACGAU Ambion, Life
PI PI NM_001003 # 1 s12239 GAGGUGACAtt Technologies
GAGCCUCAUC Ambion, Life
#2 si 94758 UGCAAUGUAtt Technologies
ACAUGGGCUU Ambion, Life
#3 si 94759 UGGUCUUUUtt Technologies
CCAGGGUAUU Ambion, Life
P2 P2 NM_001004 # 1 si 94760 GGCAAGCUUtt Technologies
GACAUGGGAU Ambion, Life
#2 si 94761 UUGGCCUUUtt Technologies
GACCGGCUCA Ambion, Life
#3 si 94762 ACAAGGUUAtt Technologies
e, eukaryotic; u, universal
CP GenBank siRNA siRNA ID siRNA sequence (5' to 3') Source
assembly accession number
factors number
HSS.RNAI. rUrCrUrUrCrUrArUrArArUrCr
NM_03219 SEQ ID N032194.12 UrUrCrUrGrUrUrArCrArUrCr
BXDC1 4 NO:l . 1 GrArA IDT
HSS.RNAI. TArArUrArCrCrUrArArUrUrCr
SEQ ID N032194.12 ArArUrCrArUrArUrCrCrArGr
NO:2 .2 CrArC IDT
HSS.RNAI. rUrCrUrUrGrCrUrUrCrUrGrCr
SEQ ID N032194.12 ArUrArUrGrArArUrCrCrUrUr
NO:3 .3 CrCrA IDT
HSS.RNAI. rUrCrCrUrCrCrUrCrCrCrUrCr
NM_01516 SEQ ID N015169.12 ArUrCrUrGrCrUrUrArUrUrGr
RRS1 9 NO:4 . 1 GrUrG IDT
HSS.RNAI. rArUrCrArGrCrCrArUrUrCrUr
SEQ ID N015169.12 UrUrGrGrUrGrUrCrGrUrCrCr
NO:5 .4 CrGrG IDT
HSS.RNAI. rCrUrUrUrCrCrUrUrCrUrUrGr
SEQ ID N015169.12 GrCrCrUrGrArArUrCrCrGrCr
NO:6 .6 UrUrG IDT
Imaging
Imaging was performed on a Zeiss Axio Observer.Zl microscope with a motorized stage, driven by
MetaMorph (MDS Analytical Technologies, Canada). Images were captured in widefield mode with a
20x objective (Plan NeoFluar, Zeiss), a LED illumination (CoolLed pE-2) and a CoolSnap HQ2 camera.
Sixteen independent fields of view were captured automatically for each well. The correct focal plane was
maintained by using the built-in autofocus module of MetaMorph. High-resolution images were captured
in confocal mode using a Yokogawa spindisk head and the HQ2 camera with a laser from Roper (405
nm 100 mW Vortran, 491 nm 50 mW Cobolt Calypso, and 561 nm 50 mW Cobolt Jive) and a 40x
objective (Plan NeoFluar, Zeiss).
PES1 detection by indirect immunofluorescence
After 3 days siRNA-mediated depletion, cells were fixed in 2% formaldehyde, washed in PBS and
blocked in PBS supplemented with 5% BSA and 0.3% Triton X-100 during 1 hour at RT. Anti-PESl
antibody (anti-rat, 1:1,000; courtesy from E. Kremmer) was diluted in PBS supplemented with 1% BSA,
0.3% Triton X-100 and incubated with the cells overnight at 4°C. Cells were washed in PBS and
incubated with a secondary Alexa Fluor 594 anti-rat antibody (1:1,000; Invitrogen) in PBS, 1% BSA,
0.3% Triton X-100 during 1 hour at RT. Cells were finally washed in PBS, treated with DAPI and imaged
with the Zeiss microscope as described above.
Image processing and iNo index
Example 2 presents the methodology for distinguishing populations of normal and altered nucleoli, based
on statistical morphometric information. Shape and textural features were first derived to characterize
nucleolar morphology in individual cell nuclei, so as to distinguish normal from altered nucleoli
morphology in FIB-GFP images. Each feature was systematically defined as a parametric function, so
that its parameters could be optimized over the entire database to maximize Fisher's criterion computed
between the distributions of the features observed in r-protein-depleted cells and SCR-treated control
cells. Given these features, we then performed a quantitative analysis of differences between their
statistical distributions in a population of r-protein-depleted cells, compared to their distributions in a
reference population. For this, we introduced a so-called discrepancy vector, each component of this
vector being associated with a specific feature, and measured the distance between the distribution
observed for a population of cells depleted of a given r-protein and that observed for a reference
population of cells (SCR-treated cells). We then defined the index of nucleolar disruption, iNo, as the Ll-
norm of the discrepancy vector. This index reflects the degree of severity of nucleolar disruption, i.e. it
ranks the r-proteins according to their impact on nucleolar structure. Additionally, Principal Component
Analysis (PCA) of the discrepancy vectors was used to extract and visualize the major trends affecting the
morphology of the nucleolus upon gene product depletion. PCA assumes linear embedding for
dimensionality reduction and allows unsupervised clustering of the nucleolar disruption phenotypes. The
computer code is described in the Supplementary information section and available upon request.
Pre-rRNA processing analysis
For the pre-rRNA analysis, we used a colon carcinoma cell line (HCT116) expressing normally p53 (39).
Northern-blot analyses were performed essentially as described in (38) and
www.RibosomeSynthesis.com. Briefly, HCT116 cells were transfected with one siRNA specific to
transcripts encoding each r-protein in 6-well plates and incubated for 2 days prior to total RNA extraction
and Northern-blot analysis. The probes used are described in Table 3. Two distinct siRNAs were used in
two independent experiments. The "R" software was used to generate and cluster the heatmaps. These
heatmaps are a visual representation of the logarithm of the ratio of the pre-rRNA level in the knockdown
condition respective to its level in the non-targeting (Scramble, SCR) control. The calibration set used
in the pre-rRNA processing analysis consists of mock-treated cells, and cells treated with a non-targeting
siRNA (Scramble, SCR), or with siRNAs specific to UTP18 or NOL9 (see Table 2 and (38) and
www.RibosomeSynthesis.com). In our clustering analysis, we did not average the processing data
obtained with the two different siRNAs used in this work for each r-protein, but rather, we considered
them as individual experiments. In most cases, the two independent processing datasets obtained for any
particular r-protein are highly clustered, demonstrating the robustness of our screens. In a few cases
(denoted with a star in Fig. 4, and observed only for two SSU and six LSU r-proteins), the heatmaps do
not belong to the same class, reflecting the inherent variation in depletion efficiency from one individual
siRNA to another. Note that all RNA species detected were used to cluster the heatmaps shown in Fig. 4c
and Fig. 4d but only those directly relevant to synthesis of the small (in panel c), or large (in panel d)
subunit are shown for simplicity. The clusters with all the RNA species are shown in Supplementary Fig.
5,6. The 28S/18S rRNA ratios were calculated from Agilent bioanalyzer electropherograms according to
the manufacturer's instructions. Examples of uncropped Northern blots are show in Supplementary Fig.
12.
Table 3
Oligo probe name RTqPCR primers
LD1818 (GAPDH Forward) TGCACCACCAACTGCTTAG SEQ ID NO: 11
LD1819 (GAPDH Reverse) GTTCAGCTCAGGGATGACC SEQ ID NO: 12
LD3657 (eL22 Forward) TTGGTGCTCTGTGGATTGAG SEQ ID NO: 13
LD3658 (eL22 Reverse) TTGCCAAAGAGCAACTGATG SEQ ID NO: 14
LD3659 (eS24 Forward) AACTGGCTTTGGCATGATTT SEQ ID NO: 15
LD3660 (eS24 Reverse) GCAGCACCTTTACTCCTTCG SEQ ID NO: 16
LD3661 (uS12 Forward) CCCACTTTCCGTAGGATCAA SEQ ID NO: 17
LD3662 (uS12 Reverse) GTCCTGAGGCTGGATATGGA SEQ ID NO: 18
LD3663 (eS 10 Forward) CGCAGAGATGTTGATGCCTA SEQ ID NO: 19
LD3664 (eS 10 Reverse) TCCAGGCAAACTGTTCCTTC SEQ ID NO:20
LD2855 (eS6 Forward) CTAGGACCAAAGCACCCAAG SEQ ID NO:21
LD2856 (eS6 Reverse) GGAAAGTCTGCGTCTCTTCG SEQ ID NO:22
LD3665 (RACK1 Forward) CAAGCTGAAGACCAACCACA SEQ ID NO:23
LD3666 (RACK1 Reverse) CACACAGCCAGTAGCGGTTA SEQ ID NO:24
LD3667 (uL23 Forward) AACTTGCCTCCATGGTTGAG SEQ ID NO:25
LD3668 (uL23 Reverse) TTGTCCTTTATTGGGCAAGG SEQ ID NO:26
LD3669 (eS7 Forward) ACGGCAGCTAAGGAAATTGA SEQ ID NO:27
LD3670 (eS7 Reverse) GTACGGCTTTTTCGAGTTGG SEQ ID NO:28
LD3671 (eL41 Forward) CTCGGCACTTAGCATCATCA SEQ ID NO:29
LD3672 (eL41 Reverse) TCCATGTTTCTGCTCCTGTG SEQ ID NO:30
LD3576 (eSl Forward) CCGGAAGAAGATGATGGAAA SEQ ID NO:31
LD3577 (eSl Reverse) TCCATGAGCTTTCCCAATTC SEQ ID NO:32
LD3673 (uS7 Forward) GTGAACGCCATCATCAACAG SEQ ID NO:33
LD3674 (uS7 Reverse) AGGCACTCAGCAATGGTCTT SEQ ID NO:34
LD2859 (eS 12 Forward) GAAGCTGCCAAAGCCTTAGA SEQ ID NO:35
LD2860 (eS 12 Reverse) AACCACTTTACGGGGTTTCC SEQ ID NO:36
LD3675 (uS19 Forward) ACAACGGCAAGACCTTCAAC SEQ ID NO:37
LD3676 (uS19 Reverse) GGAGTCATGTGCGCCTTTAT SEQ ID NO:38
LD3677 (uS15 Forward) GGACTTGCTCCTGATCTTCCT SEQ ID NO:39
LD3678 (uS15 Reverse) AGGGCAGAGGCTGTAGATGA SEQ ID NO:40
LD3679 (eL42 Forward) TGATTGCTCCTACCGACTCC SEQ ID NO:41
LD3680 (eL42 Reverse) GGCGTACAGAGAATCCTTGC SEQ ID NO:42
LD3431 (uL5 Forward) GCATCCGGAGAAATGAAAAG SEQ ID NO:43
LD3432 (uL5 Reverse) GTCCAGGCCGTAGATACCAA SEQ ID NO:44
LD3681 (eS8 Forward) TGAAGAATTGCATCGTGCTC SEQ ID NO:45
LD3682 (eS8 Reverse) TCCTCCAGGAGACTGCTGAT SEQ ID NO:46
LD3683 (eL29 Forward) ACATGGCCAAGTCCAAGAAC SEQ ID NO:47
LD3684 (eL29 Reverse) ATTGTTGGCCTGCATCTTCT SEQ ID NO:48
LD3785 (uS2 Forward) AGACGGCTGTGCTGAAGTTT SEQ ID NO:49
LD3786 (uS2 Reverse) CAGCGCAATGGTAGGTAGGT SEQ ID NO:50
LD3685 (eL15 Forward) AGCTCTCTGCTCTCCACAGG SEQ ID NO:51
LD3686 (eL15 Reverse) TGAAGGCTTCGAGCAAACTT SEQ ID NO:52
LD3687 (eS4 Forward) CCTGGATCTTTTGACGTGGT SEQ ID NO:53
LD3688 (eS4 Reverse) TTCACCCACTGCTCTGTTTG SEQ ID NO:54
LD3689 (uS5 Forward) TTATGCCAGTGCAGAAGCAG SEQ ID NO:55
LD3690 (uS5 Reverse) ATCTTGTTCCCCCAGTAGCC SEQ ID NO:56
LD3691 (P2 Forward) AGCTTGCCAGTGTACCTGCT SEQ ID NO:57
LD3692 (P2 Reverse) GGGGAGCAGGAATTTAATCA SEQ ID NO:58
LD3693 (eL31 Forward) TGCCATCAACGAAGTGGTAA SEQ ID NO:59
LD3694 (eL31 Reverse) TATTCCTTTGGCCCAGACAG SEQ ID NO:60
LD3695 (eS30 Forward) TCGCTTCTTCCTCTTTCTCG SEQ ID NO:61
LD3696 (eS30 Reverse) GGAGCACGACTTGATCTTCC SEQ ID NO:62
LD2861 (eS27L Forward) GTCTGGTAGGGCTGAGCTTG SEQ ID NO:63
LD2862 (eS27L Reverse) ACTGTCTGAGCATGGCTGAA SEQ ID NO:64
LD3697 (uS3 Forward) CTGGGCATCAAGGTGAAGAT SEQ ID NO:65
LD3698 (uS3 Reverse) CCTGTTATGCTGTGGGGACT SEQ ID NO:66
LD3699 (uS9 Forward) GGCAATGGTCTCATCAAGGT SEQ ID NO:67
LD3700 (uS9 Reverse) GGCTTTGGAGATGGACTGAC SEQ ID NO:68
LD3701 (eS 17 Forward) CCTGTGCTTCCTGTTTCCTC SEQ ID NO:69
LD3702 (eS 17 Reverse) GCTATCTTGTTGCGGAGCTT SEQ ID NO:70
LD3703 (uSll Forward) CTTTCAGGGAGGAGCTTGTG SEQ ID NO:71
LD3704 (uSll Reverse) ACCTTCATCCCACCAGTCAC SEQ ID NO:72
LD2863 (eS28 Forward) TCCATCATCCGCAATGTAAA SEQ ID NO:73
LD2864 (eS28 Reverse) AGTTACGTGTGGCGGACAAA SEQ ID NO:74
LD3705 (eL28 Forward) ACAGACATCACGGGAGGAAG SEQ ID NO:75
LD3706 (eL28 Reverse) GGACAATGCTAAGGCTGCTC SEQ ID NO:76
LD3707 (uS 14 Forward) AACCAGAGACCCTGGCTTTT SEQ ID NO:77
LD3708 (uS 14 Reverse) ACTTGGGAGGCTGAGACAGA SEQ ID NO:78
LD3709 (uLlO Forward) TCGACAATGGCAGCATCTAC SEQ ID NO:79
LD3710 (uL10 Reverse) ATCCGTCTCCACAGACAAGG SEQ ID NO: 80
LD2045 (uS13 Forward) GCAGCCATGTCTCTAGTGATCC SEQ ID NO: 8 1
LD2046 (uS13 Reverse) GGATCTTGTACTGGCGTGGA SEQ ID NO: 82
LD3711 (eS26 Forward) GAACGCATTTCCACCCTAGA SEQ ID NO: 83
LD3712 (eS26 Reverse) GCACGACCATTGTTCCTTCT SEQ ID NO: 84
LD3713 (uL24 Forward) AGGCATTTCAATGCACCTTC SEQ ID NO: 85
LD3714 (uL24 Reverse) CTGCACCCGTTCAATGTAGA SEQ ID NO: 86
LD2841 (uL18 Forward) GCAGGATGGGGTTTGTTAAA SEQ ID NO: 87
LD2842 (uL18 Reverse) ACGGGCATAAGCAATCTGAC SEQ ID NO:88
LD3715 (uS8 Forward) GACCTGGAAAAATGGCAGAA SEQ ID NO: 89
LD3716 (uS8 Reverse) CCAGAGTCCATGAGGCATTT SEQ ID NO:90
LD2005 (uS17 Forward) AAGATGGCGGACATTCAGAC SEQ ID NO:91
LD2006 (uS17 Reverse) TACCAGTGAAGGGGCATTTC SEQ ID NO:92
LD3717 (PI Forward) GGTCCTTCCGAGGAAGCTAA SEQ ID NO:93
LD3718 (PI Reverse) AACATTTACACCGGCTGCTT SEQ ID NO:94
LD3719 (eS17 Forward) ACAAGAAGAAACGCCTGGTG SEQ ID NO:95
LD3720 (eS 17 Reverse) AGTGCTGCTTCCTCCTGAAG SEQ ID NO:96
LD3721 (eL24 Forward) CAAATTCCAGAGGGCCATTA SEQ ID NO:97
LD3722 (eL24 Reverse) TTTGCTTAGGTGCTGCCTTT SEQ ID NO:98
LD2857 (uS4 Forward) GATTACATCCTGGGCCTGAA SEQ ID NO:99
LD2858 (uS4 Reverse) CGCAGAGAGAAGTCGATGTG SEQ ID NO: 100
LD3723 (uL14 Forward) CTGACAACACAGGAGCCAAA SEQ ID NO: 101
LD3724 (uL14 Reverse) ACACGCCATCTTTTCTACGG SEQ ID NO: 102
LD3725 (eS 19 Forward) TCTCCACCACTGTTCCTTCC SEQ ID NO: 103
LD3726 (eS 19 Reverse) GGTGTCTAGTGAGGGGTGGA SEQ ID NO: 104
LD2845 (uL16 Forward) AGCAAGGGTAGGTGTGCATC SEQ ID NO: 105
LD2846 (uL16 Reverse) AGACCTTTGGTCAGGTGGTG SEQ ID NO: 106
LD3727 (eS21 Forward) GCTGCTTCCTTTCTCTCTCG SEQ ID NO: 107
LD3728 (eS21 Reverse) GCCTGTGACCTTGTCAACCT SEQ ID NO: 108
p53 steady-state level analysis
For p53 steady-state analysis, we used a colon carcinoma cell line (HCT116) expressing p53 (39). For
quantitative Western-blot analysis, HCT116 cells were depleted three times independently with one
siRNA specific to transcripts encoding each r-protein. The transfection protocol used was similar to the
one described above in the rRNA processing analysis section. For total protein extractions, cells from 6-
well plates were first detached with 300 µΐ of trypsin-EDTA (ATCC) and pelleted at 100 g for 10
min at RT. Cells were washed in 1 ml of cold PBS and pelleted again at 100 g for 10 min at RT. Cells
were then lysed in 30 µΐ of lysis buffer (Tris-HCl pH 8.0, 20 mM; NP40, 0.5%; NaCl, 150 mM; EDTA, 1
mM, protease inhibitor-Roche) during 15 min on ice. Lysed cells were then centrifuged at 20,000 g for 10
min at 4°C and supernatants were recovered from the pellet of cellular debris. As controls, we used the
non-targeting scramble siRNA and an antisense oligonucleotide targeting the U8 snoRNA (IDT) (Table
2). Forty µg of total protein were separated on a 4-12 % polyacrylamide gel (Novex, Life Technologies,
Bolt Bis-Tris Plus) and transferred on low-fluorescence PVDF membrane (Immobilon-FL, Millipore)
according to the manufacturer protocol. The membranes were blocked in Odyssey blocking buffer (Li-
Cor) for 1 hour at RT. Primary antibodies (1:4,000 anti- -actin, Santa Cruz, SC69879; and 1:1,000 anti-
p53, Bethyl Laboratories, A300-247A) were added to the Odyssey blocking buffer supplemented with
0.2% Tween-20 (Sigma) and membranes were incubated overnight at 4°C with agitation. Membranes
were washed three times in TBS supplemented with 0.1% Tween-20 (TBS-T). Secondary antibodies
carrying fluorescent dyes (1:2,000 DyLight 550 anti-mouse, Thermo Scientific, 84540; and 1:2,000
IRDye 680 anti-rabbit, Westburg, 926-68071) were added to Odyssey blocking buffer supplemented with
0.1% SDS and 0.2% Tween-20 and membranes were incubated 1 hour at RT with agitation. Membranes
were washed three times in TBS-T before imaging of the fluorescent signals with the Chemidoc (Biorad).
Cellular p53 steady-state level was assessed by calculating a ratio between the red fluorescent signal
(corresponding to p53) and the green fluorescent signal (corresponding to β-actin). For each experiment,
two independent lanes corresponding to HCT116 cells treated with the SCR siRNA were loaded on the
gel, and the results from these two lanes were averaged to determine the level of p53 in this control
condition. All data were then harmonized to this averaged value in order to determine the variation in the
p53 steady-state level under this reference condition. Examples of uncropped Western-blots are shown in
Supplementary Fig. 13. In Supplementary Fig. 9, the Western-blots were performed according to the
same protocol, except that the gels were transferred onto PVDF (Amersham Hybond-P, RPN303F), and
revealed with an HRP-conjugated secondary antibody (Santa Cruz) and the Supersignal WestPico
chemiluminescent ECL substrate (Thermo Scientific). The anti-p21 antibody was purchase from Cell
signalling (2947S).
For forty-eight r-proteins whose depletion did not affect the p53 level, the residual mRNA level was
established by RTqPCR (see Supplementary Fig. 8). Reverse transcription was performed with the
qScript cDNA supermix (Quanta Biosciences). qPCR was performed on a StepOne Plus Real-Time PCR
machine (ThermoFisher Scientific) with specific primer pairs (Supplementary Table 3) and the perfecta
SYBR green supermix (Quanta Biosciences). Each reaction was performed in triplicate. The residual
level of mRNA was normalized to that of GAPDH and expressed with respect to that observed in cells
treated with a non-targeting siRNA control (SCR).
Example 2 : Image processing analysis
In this Example, we describe our procedure to extract qualitative and quantitative morphometric
information from nucleoli using a low dimensional feature vector to provide a statistically validated tool
to discriminate between populations of normal and altered nucleoli.
Overview
First, we describe how individual cell nuclei are segmented within each image of the database, in order to
localize individual cells nucleoli. Then, we present the methodology adopted to derive a small set of
shape and textural features that characterize the nucleolar morphology in each individual cell nucleus.
Finally, we present a quantitative analysis of the differences observed between the distributions of these
features in populations of cells depleted for specific gene products and the ones of a reference population.
This leads us to use dimensionality reduction techniques, to stratify and rank the r-proteins according to
their impact on the nucleolar structure. The stratification is based on a Principal Components Analysis
(PCA) of the five distances (dk, k<5) measured between the distributions observed for a population of
cells depleted for a given r-protein and those observed for a reference population of cells (SCR-treated
cells), each distribution being associated to a specific shape/texture feature. For the ranking, we introduce
an index of nucleolar disruption, or iNo, corresponding to the sum of the five absolute Idkl values.
1. Cell nuclei segmentation
As an initial step to delimit cell nucleoli from individual cells we segmented the cell nucleus. Each cell
has a single nucleus. The nucleoli are specialized subnuclear domains, which, by definition, are all
contained within the nucleus. Segmenting the nucleus, which is dense, compact and easy to score, is thus
a mean to delimit the cellular volume that contains nucleoli in each individual cell.
Nuclei are stained with the DNA stain DAPI. The nuclei contours are extracted from the DAPI channel
(blue) in two steps. Firstly, large connected components of relatively high intensity are identified using an
original adaptive thresholding method. Secondly, the connected components that show significant
concavity, indicating they likely correspond to aggregated nuclei, are rejected (Supplementary Fig. 14).
Step 1 consists in a stepwise thresholding of the DAPI images such that nuclei corresponding to
sufficiently large connected components of pixels lying above an intensity threshold are selected.
Although all parameters of samples preparation (cell seeding, transfection procedure, DAPI staining, cell
fixation, etc.) and of image capture (illumination, exposure time, etc.) are fully standardized and
automatized, we observed an inherent variability in the DAPI signal intensity of individual nuclei.
Supplementary Fig. 15 compares two extreme cases of such variability in panels (a) and (b). To address
this we adopt a hierarchical thresholding strategy that progressively refines the segmentation by
considering a sequence of K increasing thresholds, while exploiting prior knowledge about the size range
of human cell nuclei. Detailed nuclei segmentation pseudo-code is provided below.
Inputs:
: image
λ < λ2 < < k < < λκ thresholds on intensity
S : minimal area threshold for eligible connected component
Smax maximal nucleus area
dl boundary of the image (first and last rows and columns)
Output:
C set of connected components associated to segmented nuclei
- > λ
D - connected_components(I{)
C
-
{d e D Iarea > S)
For = 2 -K
Ik I > k
D - connected_components(I
Ck
For all c e Ck_
( = {d d c c} % connected components in c
Ls c = d 6 L(c) areaid) > S) % components in (c) larger than S
If ((( |«c) | = = 1) Λ ( |W c) | = = 1) Λ ( ~ ~ > 1.15)) V (fe (c) | > ))
% one big connected component with important gain in intensity
% OR at least two big connected components
Ck Ck Ls c
Else % keep c
fe - fe U { }
End if
End for all
End for
% Remove the connected components that are too big or that touch the image boundary
C 6 CK area c) < Smax A is_empty(c Π 3/))
The image processing code was programmed in MatLab. The 3-D models of ribosomal subunits were
generated with Pymol vl .5.0.3, the images for microscopy illustrations produced with ImageJ
(http://imagej.nih.gov/ij/), and the graphs generated and analyzed with Prism.
In short, let denote the k 1 intensity threshold, with 0 < k < K, and < λ + , V k < K. Let I denote the
thresholded binary image, i.e. Ik (x) = 1 if I (x) > , and 0 elsewhere, with x [1,H] x [1,W], H and W
denoting the height and width of the image, respectively. We also introduce C to denote the set of
sufficiently large (compared to a size threshold S) connected components at step k. At initialization,
includes the connected components in image L that are larger than S. The set Ck+i of connected
components at step k+1 is then derived iteratively from C and I +i , as follows. C i is initialized to the
empty set. For each connected component c C , we considered the list L(c) of connected components in
Ik+i that are included in c . If L(c) includes at least two connected components with sizes larger than S,
then those connected components are added to C
+ i . If the list L(c) includes a single connected
component c' larger than S, then either c ' or c are added to C
+ i , depending on whether the gain in mean
intensity between c and c' is larger or smaller than 15%, respectively. Note that a higher gain in mean
intensity reveals a more accurate segmentation, and that the value of 15% was set empirically. If the list
L(c) does not include any component larger than S, then c is added to C
+ i . The connected components in
CK that are smaller than a threshold Smax are expected to reasonably segment the nuclei. Practically, the
threshold S and Smax have been set to 500 and 5000 pixels, so as to include most of the size range of
human cell nuclei. Regarding , we considered a sequence of thresholds increasing from 250 to 450 by
steps of 20, and from 500 to 1300 by steps of 100. The resulting nuclei segmentation appeared to be
relatively independent of the actual sequence used, as long as its range and granularity were sufficient.
As a second step, we consider the rejection of the connected components that likely correspond to
multiple nuclei in CK- For this, we analyzed the convexity of each connected component (Supplementary
Fig. 14). Specifically, a number of lines are drawn in parallel to the two principal axis of the connected
component. When the connected component is convex, either one or zero segment lies inside the contour,
for all parallel lines. In contrast, when the connected component represents aggregated nuclei, it presents
a strong concavity and there exist parallel lines that include two or more segments lying inside the
contour. If one parallel line supports two sufficiently long inner segments that are separated by a
sufficiently long outer segment, the connected component is rejected. In Supplementary Fig. 14, the
length of the outer and inner segments respectively correspond to 0Ut, δ1 , and δ2ί . Those lengths have to
be larger than a threshold of 5 pixels to reject the component. The threshold value has been set
empirically to drastically reduce the number of multiple nuclei while keeping most of the single nuclei,
compared to a manually generated ground truth. C denotes the subset of CK that includes all and only all
non-rejected components.
Among the nuclei segmented in C, we were only really interested to analyze further those of cells in
interphase. To identify them, the DAPI image and the distribution of FIB-GFP (green channel) in the
segmented component are considered. A cell is considered to be in interphase if the DAPI is sufficiently
dense and spread (if at least 50% of the pixels in the nucleus have a normalized DAPI value larger than
0.47, with the DAPI image being normalized by its maximal value.), and if the FIB-GFP is sufficiently
localized (if at least 50% of the pixels in the nucleus have a normalized FIB-GFP value lower than 0.53,
with the FIB-GFP image being normalized by its maximal value). The thresholds were set on the basis of
a manual ground truth annotation of the images. These thresholds are quite stringent and their use results
in the loss of a small fraction of cells in interphase, however our aim to only consider cells in interphase
for further analysis is successfully achieved.
Finally, as a post-processing step, to ascertain all nucleoli of a cell are contained in each segmented
regions, we apply basic mathematical morphology to close and enlarge each connected regions.
Specifically, a dilation by a 13 x 13 structuring element was followed by a 3 x 3 erosion.
As depicted in Supplementary Fig. 15, our proposed method segments nuclei effectively, both in highly
(panel a) and weakly (panel b) contrasted DAPI images. In this figure, the set of connected components
that segment interphase nuclei are depicted in red. A reasonable detection rate was achieved, in
conjunction with a very small false positive rate. This result is well suited to our needs since we are not
interested in detecting all nuclei but rather in collecting a sufficient number of representative nucleoli
patterns samples from each FIB-GFP image.
2. Nucleoli image features
This section introduces the image features that we consider to discriminate normal and altered nucleoli
morphology in FIB-GFP images. For each segmented nucleus, its FIB-GFP signal is normalized by a
percentile of 99.9% and all the features presented in this section are computed on this normalized signal.
Section 2.1 introduces a number of original parameterized image features to measure the most significant
visual differences observed in a set of representative nucleoli. Section 2.2 optimizes the parameters of
those features, so as to maximize the discrimination between the distributions of the features in r-proteins-
depleted cells and SCR-treated control cells.
2.1 Discriminant nucleolar morphometric features
The distribution of the nucleolar masses within a cell nucleus soon appeared to be subject to important
stochastic variability. This is well illustrated in Supplementary Fig. 16, showing digitally resected
nucleoli from control cells (panel a) and from cells depleted of specific proteins of interest (panels b, c).
In these, the spatial organization of the nucleolar masses with respect to the nucleus center or to its
principal axis fluctuates substantially across the images of a given panel, and do not help in differentiating
the images from each panel. Hence, any features that would measure how the nucleolar topology is
defined in terms of the absolute and normalized position of its components are not relevant to our
problem. For example, the popular object recognition approaches that define the object appearance in
terms of the intensities and gradients observed on small patches defined by their size and location in a
normalized image do not help (12-14). The same holds true regarding transport-based features (15-17),
since they measure the discrepancy compared to a reference distribution of masses, which is not available
here.
We therefore consider the definition of a set of ad-hoc features that are independent of the actual position
of the nucleoli within the nucleus, while still reflecting the spatial spreading of the nucleolar masses.
Those features have been defined based on a manually-selected set of image samples, depicting typical
normal and abnormal nucleolus patterns (see Supplementary Fig. 16). The manual extraction of
representative samples is required to derive features that are relevant to the problem at hand, i.e. to make
sure that the set of investigated features are able to discriminate among the variety of nucleolus
appearances. However, to avoid (over)fitting our investigated features to those manually annotated
samples, in the rest of the section, each feature is systematically defined as a parametric function, so that
its parameters can be optimized over the entire database to make the feature can differentiate between
normal and gene-depleted cells images (see Section 2.2).
To derive our set of parametric features, Supplementary Fig. 16 presents a set of manually-selected cells
nucleoli images that are representative of the appearance diversity in reference control cells, and in cells
depleted of proteins of interest. Panel c (resp. b), shows that the nucleoli from cells depleted of specific
proteins of interest (resp. nucleoli with very high level of disruption) are generally spread over large
and often irregular shapes, which contrasts with the rather circular spot distribution observed in control
cells (panel a).
In addition, the 3-D graphs depicted in Supplementary Fig. 17 reveal that the distribution of FIB-GFP
intensity of normal nucleoli is smoother and less peaky than in nucleoli of cells depleted of a protein of
interest. Those observations motivated us to use features that characterize: (i) the area of support, (ii) the
shape regularity, and (iii) the variations of intensities, i.e. the texture, of the nucleolar GFP signal.
Practically, for each nucleus, all our proposed features are defined with respect to the segmentation of the
nucleolus masses into a set of disjoint connected components. This segmentation is obtained by FIB-GFP
image thresholding, which means that a pixel is considered to be part of the nucleolus if its intensity lies
above the threshold. For each feature, the segmentation threshold parameter is defined automatically
according to the method proposed in the next section, so as to maximize the separation between the
distributions of the features for SCR-treated control cells and for cells depleted of proteins of interest.
Hence, the segmentation threshold is a feature parameter, and might vary from one feature to the other.
Other feature parameters are optimized similarly, and are thus defined automatically, as described in the
next section.
Area of support:
To characterize the area of support of the nucleolus, we first consider the size and number of connected
components obtained after thresholding with a so-called area segmentation threshold a. Specifically,
- AAl measures the area of the largest connected component in the thresholded image, and
- AN denotes the number of connected components in the nucleus.
In addition, to characterize the sharpness of the intensity gradient along the frontier delimiting the
nucleolar masses, we introduced a sharpness index AS that measures the ratio of the nucleus pixels that
respectively lie above two thresholds ¾ and ¾ , with > ¾ .
Shape and texture:
To characterize the shape and the texture of the nucleolus, we only consider the largest connected
component obtained after segmentation, because the small-sized components naturally tend to reduce to
single circular peaks, making the largest connected component more representative with respect to shape
and texture.
Shape:
To quantify the nucleolus shape regularity, we adopt a shape segmentation threshold TS, and consider
three distinct shape factors to characterize the shape of the largest connected component in the segmented
image. Each factor describes the shape independently of its size.
They are illustrated in Supplementary Fig. 18, and correspond to:
- The elongation shape factor SEl , which is defined as the square root of the ratio of the two second
order moments, λι and λ2, of the connected component c around its principal axes;
- The elliptical regularity factor SRi , which is defined as the ratio between the area of the
connected component, and the area of the smallest ellipse lying outside the connected component, and
having the same center, the same principal axes, and the same elongation than the connected
component.
- The concavity factor SCi , which is defined as the ratio between the area of the connected component
and the area of its convex hull.
Texture:
To characterize the nucleolar texture pattern, after having investigated without any success (data not
shown) some conventional texture descriptors such as the local binary patterns (18), the region covariance
(19), or the grey level aura matrices (20), we introduced a number of original scalar metrics to reflect the
distribution of intensities inside the largest connected component segmented based on a texture
segmentation threshold τ,. Those metrics are:
- The texture histogram low tail index THi , which measures the percentage of pixels that lie below
some intensity threshold a , while being located inside the erosion of the connected component by a 3 x
3 pixels structuring element21. An erosion is applied to the shape to get rid of the low intensity pixels
lying on the border of the shape;
- The texture uplands index TUi , which is defined to be the number of connected regions lying above a
threshold β , while being inside the connected component;
- The texture peaks index TPi , which is defined to be the number of local maxima in the connected
component;
- The texture valleys index TVi , which is defined to be the number of local minima in the connected
component;
- The texture local minimum TLM l , which is defined as the intensity of the smallest local minimum in
the connected component;
As can be observed in Table 6 and Supplementary Fig. 19, those scalar features have reasonably distinct
values for the representative images depicted in Supplementary Fig. 16. Supplementary Fig. 19 illustrates
that the number of local minima (red dots) is generally more important in morphologically disrupted
nucleoli (panel b and c) than in control nucleoli (panel a). We thus expect that they are appropriate to
differentiate normal from altered nucleoli (see below).
Table 6. Histogram low tail index (x_t=100, a=150), number of uplands region (x_il=100,x_i2=200), and
smallest local minimum (x_a=100) (∞ indicates the absence of a local minimum) in the largest connected
component of the texture segmented images derived from Supplementary Fig. 16. (a) nucleoli from 12
SCR-treated control cells, (b) nucleoli with high level of nucleolar disruption, (c) nucleoli from cells
depleted of a protein of interest (see Supplementary Fig. 16).
1.22% 12.57% 2.83% 1.20% 1.40%
(a) 2 1 1 1 1
200 216 240
6.02% 4.05% 0% 9.12% 5.05%
2 1 1 3 1
173
31.51% 27.72% 51.30% 29.93% 4.93%
1 8 5 7 6
104 101 112 142 190(b) 29.58% 11.17% 8.57% 20.83% 7.78%
5 2 2 2 7
140
22.42% 0% 2.18% 6.83% 11.21%
6 1 1 3 10
132 165 162 118(c) 22.51% 1.77% 4.78% 6.17% 14.55%
5 2 4 1 4
111 159 149 160
2.2. Supervised optimization of features parameters
This section explains how the parameters involved in the definition of the above features are selected to
best discriminate between normal and altered nucleoli.
Following the Fisher's criterion introduced by the popular Linear Discriminant Analysis (LDA) (22), we
propose to select those parameters so as to maximize the separation between the features distributions that
we want to discriminate.
In short, the Fisher's optimization criterion considers the problem of estimating whether a feature can
discriminate between two classes of data, knowing the feature values for a representative set of data
samples from each class. A natural step to answer this question consists in looking at the average (or the
mean) of the feature values from each class. Intuitively, the closer the means are, the less discriminant the
feature is. This is because a large distance between the means implies that the gap between the classes is
expected to be large in the corresponding feature space. However, before drawing a conclusion about this
gap, we also need to account for the spreading of the features around their respective mean, so that we can
decide whether a given distance between the means is significant or not. Based on this reasoning, Fisher
has defined the separation between the distributions associated to two classes of observations to be the
ratio of the squared distance between the means to the sum of the variance within each class (22). We
adopted the same criterion to optimize the parameters of our features. In other words, a discriminant
feature is one for which the class-means are well separated, measured relative to the (sum of the)
variances of the data assigned to a particular class.
Formally, considering a feature, parameterized by a vector p lying in a parameter space P, we assume that
the feature distributions are known as a function of p, for the two classes of observations that we want to
best discriminate. Then, the Fishers' optimization criterion informs us that the vector p* that maximizes
the separation between the class distributions is defined as:
[ ) - 2(ρ)]2
where µι(ρ), 2(ρ) and σι(ρ), σ2(ρ) respectively denote the means and standard deviations of the
distributions of the feature of interest, measured with parameter p for the two classes. This Fisher's
criterion is equivalent to the Welch's adaptation of the t-test (23), widely used in image-based
morphometry (24).
Since it relies on the distributions of features that are observed for the two classes to discriminate, our
proposed parameter optimization method has to be supervised. In our case, we know by design of our
experimental set up which cells images correspond to control and (gene-depleted) test cells. Hence, we
can readily identify pairs of distributions that should be discriminated one from the other. Practically, we
selected the parameters so as to maximize the sum of the separation measured between each pair of
distributions extracted from SCR-treated control cells, and from cells depleted of a protein of interest.
Supplementary Fig. 20 presents the Fisher's optimization criterion for three different features, as a
function of their associated parameter. We observe that the parameter selection significantly impact the
discriminative power of the feature.
It is worth noting here that our methodology has been defined to limit the impact of supervision on the
outcome of the data mining process presented in Section 3. Specifically, supervision is deliberately
restricted to the independent selection of individual feature parameters, without being involved in how the
resulting features will be combined in the next section, based on a strictly unsupervised approach.
Moreover, by defining the features parameters to differentiate distributions of samples extracted from the
same culture, we avoid biasing the selection of features induced by the exploitation of a class containing
different kind of deviations compared to the reference class.
3. Nucleolar features distribution analysis
This section analyzes how the distributions of the features of nucleoli observed in SCR-treated control
cells compare to those of nucleoli of cells depleted of a protein of interest. As a primary objective, we
aimed at quantifying the degree of nucleolar disruption associated with the depletion of a specific protein,
based on the analysis of the distribution of the features of the associated nucleoli. Therefore, we
introduced a discrepancy vector. Each component of this vector is associated to a specific feature, and
measures the separation between the reference distribution and the gene-depleted distribution of interest.
We then defined the index of nucleolar disruption, or iNo, to be the LI-norm of the discrepancy vector.
This allowed us to rank the degree of severity of nucleolar disruption.
As a second and complementary outcome, we analyzed the principal components among the set of
discrepancy vectors, assuming linear embedding for dimensionality reduction. It allows for extracting and
visualizing the major trends affecting the morphology of the nucleolus when it is subject to gene-
depletion. This allowed us to regroup nucleolar disruption phenotypes in classes in an unsupervised
fashion.
3.1. Discrepancy-based distribution characterization
A discrepancy vector is defined so as to summarize how the features distributions associated to a set of
nucleoli differ from their corresponding reference distributions.
Formally, let S and S denote two sets of nucleoli images, respectively obtained from normal
reference cells and from cells that have been subject to the k gene depletion process, i.e. to the
silencer. For a given image feature f , we define the discrepancy d between set S and the reference S to
be the ratio of the difference of the mean feature values on each set to the sum of their variance. The
definition naturally extends to N features fi, 0<i<N, and the 1th component of the discrepancy vector d
associated to the set S writes
[µι (ρ ) - µ2 (ρ )]2
.
Χ (ρ )2 + σ2 (ρ )2
with ), µ ( ) and (i), σ ( ) denoting the means and standard deviations of the i feature over sets S
and S , respectively.
3.2. L I norm of discrepancy vectors
To quantify the disruption level associated with the depletion of a specific protein of interest, we defined
an index of nucleolar disruption, or iNo, as the L I -norm of the discrepancy vector computed over the set
of nucleoli images obtained from cells depleted for that given protein of interest (Fig. lc).
Letting Sk denote the set of nucleoli obtained upon treatment with silencer k, and N be the 11 features
defined in Section 2.1, the nucleolus disrup A is measured as:
3.3. Principal component analysis of discrepancy vectors
Principal components analysis (PCA) is an unsupervised method for dimensionality reduction. PCA is
used to visualize the most important phenotypic classes observed in our work. PCA searches for
directions in the data that have the largest variance, and subsequently projects the data onto it. Following
such an approach, we obtained a lower dimensional representation of the data, which removes some of
the 'noisy', supposedly less meaningful, directions.
Since we are interested to score the nucleolar disruption associated with the depletion of particular
proteins of interest, we applied the PCA to the discrepancy vectors that capture the average trends
associated with nucleoli in cells depleted with a specific silencer, and not to individual nucleolar feature
vectors.
To facilitate the interpretation of the eigenvectors associated to the principal components, we only
consider the 5 features that have the largest Fisher's score, i.e. which best discriminates normal and
altered nucleoli. Those features are listed in the first column of Supplementary Table 7.
Table 7. Two most significant PCA vectors.
Feature Principal component Second principal
component
AAi 0.4808 -0.4864
R i -0.5503 -0.6191
TH l 0.3772 0.3789
TLM l -0.4470 0.2151
TV l 0.3521 -0.4363
Fig. l b presents a PCA scatter plot depicting the 2-D points obtained by projecting each discrepancy
vector on the two most significant PCA components. We observed that the PCA analysis has successfully
found linear combinations of the proposed features that separate out the ground truth clusters,
corresponding to different levels of disruption and phenotypic classes. We indeed observe visually that
the nature of the disruption changes depending on the position in the scatter plot.
Supplementary Table 7 presents the first two principal components, i.e. the two directions of maximal
variability of the projected discrepancy vectors. It reveals the main trends in the disruption process.
From the signs of the components in the first vector, we learned that the dominant disruption process
increases the area of the nucleolus (AAlcc), and reduces its elliptical regularity (SRlcc). It also increases
the number of low intensity pixels in the segmented nucleoli (THlcc), as well as the deepness (TLMlcc)
and number of local minima (TVlcc), which reflects the scattered nature of the nucleoli spread.
The second vector induces an opposite trend compared to the one induced by the first vector, except for
the elliptical regularity (SRlcc) and for the histogram low tail index (THlcc). Hence, a positive second
PCA coefficient tends to foster the decrease of elliptical regularity, while a negative second PCA
coefficient mitigates it, compared to what would result from the single vector only. This is reflected in
Fig. l b by more regular and circular shapes of the nucleolus masses in case of negative second PCA
coefficient. In contrast, a positive second PCA coefficient corresponds to a more severe disruption, with
less regular shape than the one observed for nucleoli of similar size in absence of second PCA
component.
It is well established in the literature that inhibition of RNA polymerase I (Pol I) leads to a very specific
nucleolar morphology alterations referred to as "nucleolar segregation" or "nucleolar caps" (25). Such
caps are for example observed when cells are treated with low doses of actinomycin D, or in our
experimental set up, in cells depleted of the Pol I transcription factor TIF1A (Fig. lb, caps are seen as tiny
bright dots).
As an illustration that the PCA analysis is a powerful method to classify in an unsupervised fashion
distinct nucleolar disruption phenotypes, nucleoli of cells depleted of TIF1A, which in agreement with the
literature (25) have a markedly different nucleolar disruption phenotype by comparison to the other
control or test cells, correspond to two magenta triangles totally isolated in the upper left corner of the
graph and characterized by a negative first PCA component value, which is in contrast to most other
magenta triangles corresponding to cells depleted for other test genes.
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Example 3 : Effects of r-protein depletion on nucleolar structure
Human cells stably producing the nucleolar methyltransferase fibrillarin (FBL) fused to a green
fluorescent protein (GFP) were transfected with siRNAs targeting the appropriate transcripts, incubated
for 3 days, and imaged by fluorescence microscopy (see Methods). Each r-protein was depleted in three
experiments, a different siRNA being used in each experiment. The entire screen was duplicated. A non-
targeting siRNA (SCR), mock-treated cells (MOCK), and a calibration set were included (see Methods
and Supplementary Fig. 1). The calibration set consisted of proteins whose depletion leads to
moderate to severe nucleolar disruption, formation of nucleolar "caps" (see below), or a reduction in
fluorescence intensity (Supplementary Fig. 1).
To characterize nucleolar morphology defects both qualitatively and quantitatively, we developed a
specific image-processing algorithm (see Example 2). Briefly, we first segmented the observed nuclei on
the basis of shape- and size-consistent adaptive thresholding of a nuclear stain (DAPI signal). Then,
within each nuclear mass, GFP signal thresholding and mathematical morphology (see Example 1) were
applied to segment nucleoli into connected components. In order to optimize discrimination of nucleoli of
cells depleted of an r-protein from those of SCR-treated control cells, five shape and textural features
were extracted from the largest connected components (LCC) of each nucleolus. These five features,
selected from a set of eleven as the most discriminant ones, were: area, elliptical regularity, percentage of
pixels below an optimized intensity threshold, smallest intensity, and number of local minima (see
Methods). For each of the five features, a d value corresponding to a statistically significant distance
between the feature distribution in cells depleted of an r-protein and control cells was computed. Each
population of cells was thus characterized by five d values. Principal component analysis (PCA) was
used to reduce these five dimensions to two, allowing ready visualization of the data in a scatter plot (Fig.
lb) where each dot corresponds to a population of cells treated with one siRNA.
The PCA revealed groups of proteins whose depletion leads to similar nucleolar morphological
phenotypes (Fig. lb). Four major groups emerged. The largest one, indicated by a gray ellipse containing
the SCR control (shown as a red dot), comprises r-proteins whose depletion had no significant impact on
nucleolar structure. Importantly, most of the r-proteins are in this group, i.e. nearly all of the SSU proteins
(shown in green) and roughly two-thirds of the LSU proteins (in magenta). A second group, beneath the
SCR control, comprises proteins whose depletion did not alter the nucleolar structure but reduced the
fluorescence intensity (e.g. control cells treated with siRNAs against GFP or FBL, see also
Supplementary Fig. 1). Cells depleted of the RNA Pol I transcription factor TIF1A formed distinctive
"nucleolar caps", in keeping with the known effects of RNA Pol I inhibitions (14), and appeared isolated
in the upper left part of the graph. The fourth group comprises the few r-proteins whose depletion was
found to impact nucleolar structure very severely, remarkably they are almost exclusively LSU proteins.
This cluster forms a tail in the right part of the graph. In cells depleted of these major contributors to
normal nucleolar structure, the nucleoli were detected as "unfolded beaded necklaces" (Fig. lb). Our
automated classification was benchmarked with a manual one and found to be extremely robust
(Supplementary Fig. 2).
To stratify the r-proteins according to the severity of nucleolar disruption caused by their absence, we
defined an index of nucleolar disruption (iNo) as the sum of the absolute values of the five d distances
(see Methods). For each r-protein, an average iNo, based on the values obtained with the three different
siRNAs used, was calculated and plotted. In the resulting graph, the r-proteins are listed from top to
bottom in the order of increasing impact on nucleolar structure (Fig. lc). As concluded from the PCA,
depletion of most r-proteins appears to have no significant impact on nucleolar structure (iNo <0.05), and
the proteins whose depletion has the greatest effect belong to the LSU (magenta). Unexpectedly, the r-
proteins uL5 (formerly RPL11, (24)) and uL18 (formerly RPL5) appear among the strongest contributors
to maintenance of nucleolar structural integrity (Fig. lc). These are precisely the proteins which, together
with the 5S rRNA, form a small ribonucleoprotein complex, the 5S RNP, which acts as an HDM2 trap
and controls the steady-state level of p53 in a regulatory circuit known as p53-dependent anti-tumor
nucleolar surveillance (25, 26). Briefly, in unstressed cells, p53 is constitutively targeted for proteosomal
degradation by Hdm2-mediated ubiquitination. In the event of a nucleolar stress, such as a ribosome
biogenesis dysfunction, unassembled ribosomal components accumulate. These include the 5S RNP,
which interacts with Hdm2, sequestering it away from p53. As a result, p53 is stabilized and induces cell
cycle arrest and cell death (9). In mature 60S subunits, the 5S RNP constitutes the central protuberance
(CP), a late-assembling structure (see below).
Ribosomal subunit assembly is a sequential process involving progressive binding of r-proteins to nascent
rRNAs and gradual formation of ribosomal landmarks (23, 27-31). We wondered if the r-proteins
important for nucleolar structure might map to particular areas on mature ribosomal subunits. Color-
coding of the r-proteins according to their iNo values, on a 3-D model based on the crystal structure of the
human ribosome32 (Fig. 2a), made it obvious that the strongest contributors to nucleolar structure
maintenance belong to the LSU and are not randomly distributed over it: rather, they are preferentially
located at the subunit interface in areas corresponding to the CP, the LI -stalk, and a region directly below
the Ll-stalk (Fig. 2a). All of these are late-forming structures (see below).
The nucleolus is a highly dynamic structure capable of responding through profound morphological
alterations to cellular stresses such as drug treatment or viral infection (20). In interphase, however, it is
quite stable. It is disassembled at the onset of mitosis and reassembled at the end of this process (14). In
our nucleolar screens, cells were imaged after three days of r-protein depletion, as we reasoned that cells
might have to undergo at least two cycles of nucleolar breakdown/nucleolar genesis for nucleolar
alterations to become readily detectable. This assumption was confirmed when we established the time
course of the appearance of nucleolar morphological defects (Supplementary Fig. 3). Focusing on thirteen
representative r-proteins, and monitoring changes at 24-h intervals over a 3-day depletion period, we
indeed found nucleolar disruption to increase steadily (Supplementary Fig. 3b), in parallel with an
increase in iNo values. Nucleolar disruption became obvious only after 72 h of depletion (Supplementary
Fig. 3a).
The nucleoli of cells of amniotic organisms have three nucleolar subcompartments (12,13,33). In our
original screens, we used FBL, a dense fibrillar component (DFC) marker, to assess nucleolar
morphology. To extend our conclusions, we examined whether nucleolar structural defects due to r-
protein depletion might be equally observable with a marker of a different nucleolar subcompartment. We
chose to monitor by immunofluorescence a granular component (GC) marker, the PESl antigen, in
depletion experiments focusing on thirteen representative r-proteins (Supplementary Fig. 4). As expected
for a GC protein, PESl staining was peripheral to the FBL signal (Supplementary Fig. 4b). Remarkably,
we observed extreme closeness between the iNo scores computed from the FBL and PESl signals, and
the ranking of r-proteins according to phenotype severity was largely similar (Supplementary Fig.
4a). We conclude that the nucleolar structural defects due to r-protein depletion can be monitored
similarly with a DFC or a GC antigen.
We conducted our nucleolar screens in HeLa cells because of the large size of their nucleus, which makes
them ideal for use in high-throughput screens with visual readouts (e.g. 34, 35). To see how general the
effects observed in HeLa-GFP-FBL cells might be, we tested five cell lines: two cervical carcinoma cell
lines (HeLa-GFP-FBL and HeLa), one colon carcinoma cell line (HCT116), and two lung cancer cell
lines (A549 and H1944). We selected eight representative r-proteins, depleted them for three days in each
of the five cell lines, and monitored nucleolar structure by immunostaining of endogenous PESl and iNo
score computation (Fig. 3). For the r-proteins tested, we found the weak and strong contributors to
nucleolar structure maintenance to be largely the same in all five cell lines (Fig. 3), with uL5 and uL18
playing an important role in each case.
Example 4 : Effects of r-protein depletion on pre-rRNA processing
In an attempt to correlate the effects of r-protein depletion on nucleolar structure with defects in ribosome
biogenesis, we determined which r-proteins are essential to pre-rRNA processing (Fig 4). Mature rRNAs
are produced from long precursor molecules. They are embedded in non-coding spacers and require
extensive processing to be generated (2, 36). Pre-rRNA processing analysis is a good proxy for ribosomal
assembly analysis, because failure of an r-protein to bind to nascent ribosomes leads to ribosome
biogenesis blockade, pre-rRNA processing inhibitions, and subunit biogenesis abortion (23, 30, 31, 37).
The synthesis of each of the eighty r-proteins was knocked down for 2 days in HCT116 cells with an
appropriate siRNA. Total RNA was then extracted, run on a bioanalyzer, and analyzed by high-resolution
quantitative northern blotting. Two different siRNAs were used for each r-protein and yielded largely
similar results (Fig 4). As controls, we used UTP18 and NOL9 because their depletion leads to well-
established pre-rRNA processing defects (Supplementary Figs 5,6,11; see (38)). As further controls, non-
targeting siRNA (SCR) and mock-treated cells were used (Supplementary Figs 5,6). HCT116 and HeLa
cells are both of epithelial origin and, as shown above, their nucleolar structure is similarly affected by r-
protein depletion (Fig. 3). We performed our RNA processing work and p53 steady-state accumulation
analysis (see below) on HCT116 cells because, unlike HeLa cells, they express p53 normally39. For the
RNA analysis, cells were depleted for only 2 days, as we had established beforehand, precisely in
HCT116 cells, that bona fide pre-rRNA processing inhibitions are early defects preceding cell-cycle
arrest and apoptosis and are best captured at this time point (discussed in (38)).
The ratio of 28S to 18S mature rRNA was extracted from bioanalyzer electropherograms (Fig. 4a). The
accumulation of small subunit 18S rRNA was strongly decreased, and the 28S/18S ratio accordingly
increased, by SSU r-protein depletion (Fig. 4a). Reciprocally, LSU r-protein depletion led to decreased
accumulation of the large subunit 28S rRNA and to a reduced 28S/18S ratio (Fig. 4a). Northern blots
were probed with specific radioactively labeled oligonucleotides, revealing all major known pre-rRNA
intermediates (Fig. 4b, Supplementary Figs. 5,6,11). Each band detected was quantified with a
phosphoimager and normalized with respect to the SCR control. The signals were represented on
heatmaps (Fig. 4c for SSU r-proteins, Fig. 4d for LSU r-proteins and Supplementary Fig. 11; see also
(38)). The heatmaps were clustered with the software "R", revealing functionally related groups of r-
proteins whose depletion affects similar processing steps (Fig. 4c,d, and Supplementary Figs S5,6 and
Supplementary Fig. 11). For the SSU r-proteins, three groups emerged: proteins whose depletion affects
early processing (class 1), late processing (class 3), or has no significant effect on processing (class
2)(Fig. 4c, see representative examples in Supplementary Fig. 5 and Supplementary Fig. 11 for a full
dataset). Our classification of the SSU r-proteins corresponds largely to that previously established in
HeLa cells (23). We identified four classes of LSU r-proteins (Fig. 4d and Supplementary Figs. 6,11):
those whose depletion affects early cleavage steps (class 1), intermediate cleavage steps (class 3), late
cleavage steps (class 4), or has no substantial impact on processing (class 2)(Fig. 4d and Supplementary
Fig. 6). Importantly, no such classification of LSU r-proteins has been reported previously. Our
classification of r-proteins' involvement in pre-rRNA processing thus confirms and largely extends
previous work (Supplementary Fig. 7).
The r-proteins were mapped on a 3-D model of the human ribosome according to their involvement in
processing (Fig. 2b). This revealed, on both subunits, a strikingly asymmetric distribution. On the mature
small subunit, the r-proteins required for early processing steps are those forming the body and platform
(Fig. 2b), both of which are known as early-assembling subunit structures (27,28,40). The r-proteins
affecting late cleavage steps, in contrast, correspond to the head and beak (Fig. 2b), which are late-
forming structures (27,28,40). On the large subunit, the r-proteins important for early processing are
mainly exposed on the solvent side of the ribosome (in blue on the right-hand-side cartoon Fig. 2b), while
those required for intermediate cleavages are at the interface side (in orange on the left-hand-side
cartoon), below the LI stalk, and those important for late processing correspond largely to the CP and Ll-
stalk (in red). Remarkably, this is precisely the order in which these structures have been shown to form
in budding yeast (30).
A comparison of our nucleolar structure and rRNA processing data reveals that the r-proteins whose
depletion has the greatest effect on nucleolar structure (in red in Fig. 2a) are largely those required for
intermediate or late processing steps in the formation of the large ribosomal subunit (in orange and red in
Fig. 2b). Within this subunit, they belong mostly to late-assembling structures, including the Ll-stalk and
CP (uL5 and uL18). In conclusion, while practically all r-proteins appear important for pre-rRNA
processing, most of them have no incidence on the structural integrity of the nucleolus.
Several trans-acting factors, including BXDC1 and RRS1, are required for CP assembly (26,41). This
function is conserved between yeast and human (26,41). Considering the strong effect of uL5 or uL18
depletion on nucleolar structure, and because both of these proteins are CP components, we predicted that
depletion of factors involved in CP formation should also cause profound nucleolar structure alterations.
This proved to be true: we found depletion of BXDC1, RRS1, or both to affect nucleolar structure
severely (Fig. 5a), almost as strongly as does uL5 or uL18 depletion (Fig. 5b).
Example 5 : Effects of r-protein depletion on p53 steady-state levels
Given the numerous connections between p53 and ribosomal component synthesis on the one hand (42),
and between the functional integrity of the nucleolus and p53 metabolic stability on the other (43), we
examined systematically how depletion of each individual r-protein might affect the steady-state level of
p53. Colon carcinoma cells expressing p53 (HCT116 p53+/+, (39)) were transfected with one siRNA
targeting each r-protein transcript and incubated for 2 days. In this analysis we used a single siRNA,
selected on the basis of its proven efficacy in the nucleolar and processing screens, and carried out
depletion for 2 days to allow a direct comparison with the RNA analysis. Total protein was then extracted
and analyzed by quantitative fluorescent western blotting (Fig. 6a and Supplementary Fig. 11).
The p53 steady-state level increase observed ranged from 0 to 10-fold (Fig. 6b). About a third of the r-
proteins (24/80) were found to affect p53 level at least 5-fold (Fig. 6b, gray box), the cut-off we adopted
arbitrarily as significance threshold. As observed for the effects on nucleolar structure, we found nearly
all of these r-proteins to belong to the LSU, the sole exception being eS31. Interestingly, depletion of uL5
or uL18, involved in p53-dependent nucleolar surveillance (discussed above), had no significant impact
on the p53 steady-state level, in keeping with previous reports (25,26,44) and in contrast to the role of
these proteins in forming an Hdm2 trap when they accumulate in cells (44-46). As an additional control
we established by RTqPCR, for forty-eight r-proteins whose depletion did not significantly affect p53
accumulation (see Fig. 6b, from eL22 to eS21), the efficiency of r-protein depletion at the mRNA level
(Supplementary Fig. 8). We found depletion to be effective for all the r-proteins tested, the residual
mRNA level for most of them (40 out of 48) being below 20%. Note that 3 1 of the 48 candidates tested
showed a marked processing defect upon depletion (see Fig. 4, Supplementary Figs S5,S6,S11), a further
indication that depletion was efficient.
In view of the model of nucleolar stress above, we wondered if the significant increase in p53 observed
upon depletion of 24 r-proteins might involve uL5 and uL18. We found this to be the case: co-depletion
of any one of the 24 r-proteins and either uL5 or uL18 led to normal levels of both p53 and its
transcriptional target p21 (Supplementary Fig. 9a). The effects of BXDC1 and RRS1 were also
investigated. As expected from the role of these proteins as ribosome (CP) assembly factors, their
depletion also caused p53 and p21 to increase, and this rise was dependent on uL5 and uL18
(Supplementary Fig. 9b).
Figure 2c shows the distribution of the r-proteins on mature subunits according to their impact on p53
expression. This shows that the significant contributors to p53 homeostasis all correspond to late-
assembling structures on the subunits (Fig. 2b,c).
Table 5. Comparison between the effects of r-protein depletion on nucleolar structure integrity and p53
homeostasis

The r-proteins are listed according to a recently revised nomenclature (Ban et al, 2014, PMID 24524803).
The former nomenclature is provided in parentheses. The index of nucleolar disruption (iNo score) ranges
from 0 (normal nucleolus) to 0.2 (disrupted nucleolus) (see Fig 1C). The iNo values were computed from
two independent screens (screen I/screen II). The p53 level is expressed in fold increase (from 0 to 10.4,
see Fig 4B). Arbitrarily set significance cut-off: p53 fold increase > 5 ; iNo > 0.1. ark grey, above cu t
off; medium grey, below cut-off; white, curated "near cut-off cases. SSU, small subunit r-protein; LSU,
large subunit r-protein; iNo, index of nucleolar disruption. The iNo scores and p53 levels were established
in epithelial human cells. The iNo scores were determined in HeLa-FBL-GFP cells after r-protein
depletion for 3 days; the p53 levels in HCT1 16 p53 +/+ cells after r-protein depletion for 2 days.
No effect on nucleolar structure & no effect on p53 level: 50 r-proteins
No effect on nucleolar structure & p53 induction: 2 1 r-proteins
Effect on nucleolar structure & no p53 induction: 2 r-proteins (uL5 and uL18)
Effect on nucleolar structure & p53 induction: 8 r-proteins
uL5 and uL18 are unique in that, remarkably, they are the only two r-proteins, out of eighty, whose
depletion impact strongly nucleolar structure without inducing p53.
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Claims
1. A method for predicting, diagnosing, or determining nucleolar disruption or integrity, comprising
determining the protein or mRNA expression level of one or more, such as two or more, such as three or
more, such as all (ribosomal) protein selected from the group comprising or consisting of any of (a) to
(PP):
(a) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL22, eL20, uL15, eL27, eL14, eL37,
eL39, eL34, uL6, eL36, eL13, and eL33 ;
(b) uLl, uL2, eL21, eL38, uL13, uL22, eL14, eL39, eL34, eL13, eL8, and eL33;
(c) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eL13, eL8, and eL33;
(d) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eS31, eL13, eL8, and eL33;
(e) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eL13, eL8, eL33, eL32, eL6, uL4, uL3, eL18, uLll, eL40, uL16,
uL14, and eL24;
(f) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eS31, eL13, eL8, eL33, eL32, eL6, uSIO, uL4, uL3, eL18, uLll,
eS25, eL40, eS21, uL16, eS19, uL14, uS4, eL24, eS27, uS17, and uS8;
(g) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eL13, eL8, eL33, eL32, eL6, uL4, uL3, eL18, uLll, eL40, uL16,
uL14, eL24, uLlO, eL28, eL27L, eS30, eL31, eL15, and eL29;
(h) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eS31, eL13, eL8, eL33, eL32, eL6, uSIO, uL4, uL3, eL18, uLll,
eS25, eL40, eS21, uL16, eS19, uL14, uS4, eL24, eS27, uS17, uS8, uL24, eS26, uS13, uLlO,
eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14;
(i) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL31, eL6, eL20,
uL15, eL27, eL14, uL4, eL37, eL39, eL34, uL6 , eL13, and eL36;
(j) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL31, eL6,
eL20, uL15, eL27, eS30, eL14, uL4, eL37, eL39, eL34, uL6, eS19, eSlO, eL13, eS31, and eL36;
(k) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL31, eL6, eL20,
uL15, eL27, eL14, uL4, eL37, eL39, eL34, uL6 , eL13, eL36, eL33, and eL8;
(1) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL33, eL8,
eL13, eS31, eL36, eSlO, eS19, uL6, eL34, eL39, eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6,
and eL31;
(m) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL33, eL8, eS27,
eL36, uL24, eL18, eL32, eL29, uL16, eL24, eL15, eL42, uLlO, eL13, uLll, eL40, uL3, uL6,
eL34, eL39, eL37, uL4, eL14, eL27, uL15, eL20, eL6, and eL31;
(n) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL33, eS24,
eL8, uS4, eS28, eS27, uS7, uS9, uS19, eL36, uSll, uS8, uL24, eL18, eL32, eS27L, eL29, uL16,
uS13, eL24, eL15, uSIO, eSlO, eL42, uLlO, eL13, eS31, uLll, eL40, uL3, eS19, uL6, eL34, eL39,
eL37, uL4, eL14, eS30, eL27, uL15, eL20, eL6, eL31, and uS14;
(o) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eS31, eL13, eL8, eL33, eL32, eL6, uSIO, uL4, uL3, eL18, uLll,
eS25, eL40, eS21, uL16, eS19, uL14, uS4, eL24, eS27, uS17, uS8, uL18, uL24, eS26, uS13,
uLlO, eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, and
uS14;
(p) uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL20, uL15, eL27, eL14,
eL37, eL39, eL34, uL6, eL36, eL13, eL8, eL33, eL32, eL6, uL4, uL3, eL18, uLll, eL40, uL16,
uL14, eL24, uL24, uL18, uLlO, eL28, eL27L, eS30, eL31, eL15, and eL29;
(q) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL31, eL6,
eL20, uL15, eL27, eS30, eL14, uL4, eL37, eL39, eL34, uL6, eS19, and eSlO;
(r) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL31, eL6,
eL20, uL15, eL27, eS30, eL14, uL4, eL37, eL39, eL34, uL6, and eS19;
(s) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL31, eL6, eL20,
uL15, eL27, eL14, uL4, eL37, eL39, eL34, and uL6;
(t) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL31, eL6,
eL20, uL15, eL27, eS30, eL14, uL4, and eSlO;
(u) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL31, eL6, eL20,
uL15, eL27, eL14, and uL4;
(v) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, uS14, eL31, eL6,
eL20, and eSlO;
(w) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, uL22, eL31, eL6, and
eL20;
(x) uL18, uL5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, uL30, and uL22;
(y) ull8, ul5, uLl, uL2, eL43, eL21, eL19, eL38, uL13, eL30, uL29, and uL30;
(z) ul 8, ul5, uLl uL2, eL43, eL21, eL19, eL38, uL13, uL29, and eL30;
(aa) ul 8, ul5, uLl uL2, eL43, eL21, eL19, eL38, and uL13;
(bb) ul 8, ul5, uLl uL2, eL43, eL21, eL19, and eL38;
(cc) ul 8, ul5, uLl uL2, eL43, eL21, eL19, and eSlO;
(dd) ul 8, ul5, uLl uL2, eL43, eL21, and eL19;
(ee) ul 8, ul5, uLl uL2, eL43, eL21, and eSlO;
(ff) ul 8, ul5, uLl uL2, eL43, and eL21;
(gg) ul 8, ul5, uLl uL2, eL43, and eSlO;
(hh) ul 8, ul5, uLl uL2, and eL43;
(ii) ul 8, ul5, uLl and uL2;
(jj) uL18, uL5, and uLl;
(kk) uL5, anduL18;
(11) uL18;
(mm) uL5;
(nn) BXDC1 and RRS1, or any protein involved in ribosomal central protuberance formation;
(00) any one or more ribosomal protein selected from the above lists, except uL24, uL14, eS7, eL8, eS6,
eS19, uSll, eL37, eS26, eS31, eS27L, uS12, and uSIO; or
(pp) any one or more ribosomal protein selected from the above lists, except uL5 and/or uL18.
2. A method for increasing or decreasing the protein level of p53 in a cell, comprising respectively
decreasing or increasing the mRNA or protein level of one or more, such as two or more, such as three or
more, such as all ribosomal proteins selected from the group comprising or consisting of any of (a) to (i):
(a) eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18,
uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27,
uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, anduLl;
(b) eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, eL24, uL14, uL16, eL40, uLll, eL18, uL3, uL4,
eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30,
uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(c) uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll, eL18, uL3, uL4, uSIO,
eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22,
uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(d) eL24, uL14, uL16, eL40, uLll, eL18, uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34,
eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2,
and uLl;
(e) eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29,
eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(f) eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20, uL22, uL30, uL29, eL30,
uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(g) eL33, eL8, eL13, eL34, eL39, eL14, uL22, uL13, eL38, eL21, uL2, anduLl;
(h) eL29, uS2, eL15, eS4, uS5, eL31, eS30, eL27L, uS3, uS9, eS17, uSll, eS28, eL28, uS14, uLlO,
uS13, eS26, uL24, uL18, uS8, uS17, eS27, eL24, uS4, uL14, eS19, uL16, eS21, eL40, eS25, uLll,
eL18, uL3, uL4, uSIO, eL6, eL32, eL33, eL8, eL13, eS31, eL36, uL6, eL34, eL39, eL37, eL14,
eL27, uL15, eL20, uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, and uLl;
(1) eL29, eL15, eL31, eS30, eL27L, eL28, uLlO, uL24, uL18, eL24, uL14, uL16, eL40, uLll, eL18,
uL3, uL4, eL6, eL32, eL33, eL8, eL13, eL36, uL6, eL34, eL39, eL37, eL14, eL27, uL15, eL20,
uL22, uL30, uL29, eL30, uL13, eL38, eL19, eL21, eL43, uL2, anduLl;
3. An inhibitor or inducer of one or more ribosomal proteins selected from the group comprising or
consisting of any of (a) to (pp) as defined in claim 1 or any of (a) to (i) as defined in claim 2 for use in
respectively increasing or decreasing the protein level of p53 in a cell, or for use in therapy, or for
use in altering nucleolar morphology, architecture, or integrity.
4. A method for characterizing nucleolar morphology, architecture, or integrity, comprising
measuring or determining one or more morphometric characteristics of the nucleolar support area and the
nucleolar intensity pattern;
optionally wherein the morphometric characteristics are defined by parametric functions,
preferably to characterize, in a measurable and quantifiable manner, the visual appearance of the
nucleolus in an image, including morphology or form (encompassing size, shape, and number of
subcomponents) and inner pattern structure (encompassing spatial organization and spatial variation of
pixel intensity).
5. The method according to claim 4, wherein nucleolar morphology, architecture, or integrity is
characterized based on eukaryotic cell or tissue images, preferably based on a population of cells.
6. The method according to claim 4 or 5, which is a computer implemented method and/or an
automated method.
7. The method according to any of claims 4 to 6, comprising the steps:
a) obtaining or providing an image of one or more eukaryotic cell, or eukaryotic tissue, or
preferably of a population of cells ;
b) optionally segmenting said image thereby obtaining individual cells or cell nuclei;
c) segmenting said image, thereby obtaining one or more nucleolar masses, preferably comprising
or consisting of a plurality of connected pixels, which connected pixels constitute or represent a nucleolar
connected component;
d) optionally assigning by colocalization nucleolar masses to individual cells or cell nuclei and
thus to individual cells;
e) extracting for each cell or nucleus one or more morphometric characteristic characterizing the
support area, and/or the intensity pattern of the nucleolar connected components optionally assigned to
the cell, preferably the largest one;
f) computing probabilistic distributions (over the set of cells) of said morphometric
characteristics; and
g) comparing said probabilistic distributions with a reference model distribution and/or
determining the overlap of said probabilistic distributions to a reference model distribution.
8. The method according to any of claims 4 to 7, comprising defining a set of discriminant nucleolar
morphometric characteristics, preferably derived by:
a) optionally providing or obtaining cell (population) or tissue image samples from cell(s)
(populations) or tissues that have to be differentiated;
b) defining a set of arbitrary parametric nucleolar morphometric characteristics to capture the
main salient differences observed between representative cell nucleolus samples of two populations of
interest;
c) selecting the parameters associated to each nucleolar morphometric characteristic to
maximize its discriminating power, i.e. to minimize the overlap between the morphometric characteristic
probabilistic distributions derived from the cell(s) (populations) to differentiate;
d) selecting as discriminant morphometric characteristics the morphometric characteristics and
their associated optimized parameters leading to a large separation between cell(s) (populations) to
discriminate.
9. The method according to any of claims 4 to 8,
wherein said nucleolar support area is characterized by morphometric characteristics that
determine the size and shape of the spatial support of the nucleolar masses, preferably wherein said
morphometric characteristics count the number of distinct nucleoli or distinct connected components
contributing to the nucleoli, and/or the number of pixels that are part of each of those components, and/or
wherein said morphometric characteristics include any quantitative metric that reflects the elongation,
(e.g. aspect ratio), and/or elliptical regularity, and/or concavity of the nucleolar masses; preferably
wherein all morphometric characteristics are parametrized by the level of (pixel) intensity above which a
pixel is considered to be part of the nucleolar masses; and/or
wherein said nucleolar intensity pattern is characterized by morphometric characteristics that
determine the nucleolar intensity patterns and/or nucleolar connected components intensity patterns,
preferably the spatial variation of the nucleolar signal within the nucleoli or nucleolar connected
components, preferably the largest one; wherein spatial variations are preferably measured inside and on
the boundary of the nucleoli or nucleolar connected components, and wherein preferably in the
neighborhood of the boundary of a nucleolus or nucleolar connected component, the sharpness of
transition of nucleolus-related pixel intensity between the nucleolar mass and the background image is
measured; and wherein preferably inside a nucleolus or nucleolar connected component, the
morphometric characteristics are defined to capture the spatial variations of pixel intensities; optionally
wherein the magnitude and/or number of local minima and/or local maxima of nucleolus-related pixel
intensity values are measured, and/or the number of pixels having a relatively small intensity value and/or
the number and/or shape of high intensity sub-regions that are separated by small intensity valleys inside
a nucleolus or nucleolar connected component, preferably wherein all morphometric characteristics are
parametrized by thresholds adopted to define the notions of small/high intensity, and/or by the structuring
elements considered to define the notions of inside/outside a nucleolus or nucleolar connected
component, preferably based on mathematical morphology.
10. The method according to any of claims 7 to 9, wherein segmenting involves determining whether
or not the intensity of a pixel lies above a threshold, and preferably wherein the pixel is considered to be
part of the physical element of interest, such as nucleus or nucleolus, when the intensity of the pixel lies
above the threshold; wherein the threshold is preferably determined automatically;
optionally wherein the threshold considered for segmentation is defined using an automatic and
locally adaptive method that selects the threshold within a pre-defined set of values, preferably as the
largest value for which the area of the connected set of pixels above the threshold is larger than a
lower bound of the size expected for the physical element such as a nucleus or nucleolus to segment;
and/or
optionally wherein the threshold considered for segmentation is defined to maximize the
discriminant power of said discriminant nucleolar morphometric characteristics.
11. The method according to any of claims 4 to 10,
wherein said nucleolar support area is determined by measuring the nucleolus area, preferably of
the largest nucleolus or largest nucleolar connected component in a cell, the number of nucleoli or
nucleolar connected components in a cell, and/or the sharpness index, preferably of the largest nucleolus
or largest nucleolar connected component in a cell;
optionally, wherein the sharpness of transition of nucleolus-related pixel intensity between the
nucleolus of nucleolar connected component and the background image is measured as the ratio of the
nucleolar pixels that respectively lie above two pixel intensity thresholds Xi and x2, with Xi > x2.
12. The method according to any of claims 4 to 11, wherein said nucleolar support area is determined
by measuring the nucleolar support shape regularity, preferably by measuring the elongation shape factor,
the elliptical regularity factor, and/or the concavity factor preferably of the largest nucleolus or largest
nucleolar connected component in a cell; preferably by measuring the elliptical regularity factor;
optionally, wherein said elongation shape factor is determined based on the two second order
moments λ and λ2 of the nucleolus or nucleolar connected component around its principal axes,
preferable as the square root of the ratio of the two second order moments λ and λ2 of the nucleolus or
nucleolar connected component around its principal axes,
optionally, wherein the elliptical regularity factor is determined as the ratio between the area of
the nucleolus or nucleolar connected component and the area of the smallest ellipse lying outside the
nucleolus or nucleolar connected component and having the same center, the same principal axes, and the
same elongation as the nucleolus or nucleolar connected component, and/or
optionally, wherein the concavity factor is determined as a decreasing function of the ratio
between the area of the nucleolus or the nucleolar connected component and the area of its convex hull.
13. The method according to any of claims 4 to 12, wherein said nucleolar intensity pattern is
determined by measuring the distribution of pixel intensities preferably in the largest nucleolus or largest
nucleolar connected component in a cell; preferably following cell-wise dynamic range normalization;
preferably by measuring the texture histogram low tail index, the texture uplands index, the texture peaks
index, the texture valleys index, and/or the texture local minimum, preferably of the largest nucleolus or
largest nucleolar connected component in a cell; preferably by measuring the texture histogram low tail
index, the texture valleys index, and the texture local minimum;
optionally, wherein the texture histogram low tail index is defined as the percentage of pixels that
lie below a pixel intensity threshold a ,
optionally wherein the texture uplands index is defined as the number of connected nucleolar
pixels having their intensity above a threshold β,
optionally wherein the texture peaks index is defined as the number of local maxima in the
nucleolus or nucleolar connected component,
optionally wherein the texture valleys index is defined as the number of local minima in the
nucleolus or nucleolar connected component, and/or
optionally wherein the texture local minimum is defined as the intensity of the smallest local
minimum in the nucleolus or nucleolar connected component.
14. The method according to any of claims 4 to 13, comprising determining:
- the area of the largest nucleolus in a cell;
- the elliptical regularity factor;
- the texture histogram low tail index;
- the texture valleys index; and
- the texture local minimum.
15. The method according to any of claims 4 to 14, wherein the nucleolus is identified based on
image pixel intensity thresholding, preferably in an image obtained by identifying or quantifying a
nucleolus-specific feature (e.g. density, optical height) or marker (e.g. nucleolus specific or enriched
molecule), such as FBL or PES1; preferably as a connected component in a thresholded image;
optionally wherein the nucleolar support area is determined based on an area segmentation
threshold, wherein the nucleolar shape regularity is determined based on a shape segmentation threshold,
and/or the nucleolar texture pattern is determined based on a texture segmentation threshold, each
threshold being preferably defined to maximize the discriminant power of corresponding morphometric
characteristics.
16. The method according to any of claims 4 to 15, wherein the nucleolar morphology, architecture,
or integrity is compared to a standard or reference nucleolar morphology, architecture, or integrity, and
preferably wherein the nucleolar morphology, architecture, or integrity is scored based on the discrepancy
with respect to the standard or reference nucleolar morphology, architecture, or integrity, preferably
wherein said standard or reference nucleolar morphology, architecture, or integrity is a normal nucleolar
morphology, architecture, or integrity.
17. The method according to claim 16, wherein said discrepancy is determined as a discrepancy
vector based on the distances between the distributions of each morphometric characteristic of a
population of said nucleoli or nucleolar connected components and the distribution of the corresponding
morphometric characteristic of a population of standard or reference nucleoli or nucleolar connected
components, wherein the discrepancy vector component associated with a given morphometric
characteristic (i) for a particular nucleolus or nucleolar connected component population d is preferably
determined according to the following formula representing a discrepancy vector component:
d ( =
wherein µ(ί ) and µ (ί ) are the mean of morphometric characteristic (i) of said nucleoli or
nucleolar connected components and said standard or reference nucleoli or nucleolar connected
components, respectively; and wherein σ( ) and σ ( ) are the standard deviation of morphometric
characteristic (i) of said nucleoli or nucleolar connected components and said standard or reference
nucleoli or nucleolar connected components, respectively.
18. The method according to any of claims 4 to 17, wherein nucleolar morphology, architecture, or
integrity is characterized based on the index of nucleolar disruption (iNo) which is derived from an
increasing function of the absolute value of the morphometric characteristic discrepancy vector
components, preferably as the Ll-norm of the discrepancy vector, wherein said iNo is determined
according to the following formula:
wherein N is the number of morphometric characteristics; wherein a(i) is a weighing factor for the i
morphometric characteristic, wherein preferably 0 < a(i) < 1; and wherein d(i) is the discrepancy vector
component for the 1th morphometric characteristic.
19. The method according to any of claims 7 to 18, further comprising regrouping nucleolar
disruption phenotypes in classes and/or presenting them in lower dimension by means of unsupervised
clustering and/or principal components analysis.
20. A method for scoring, quantifying, or classifying nucleolar disruption and/or for determining the
health status of an individual or of a cell or tissue or for diagnosis, comprising performing the method
according to claim 18 or 19, wherein the iNo value is indicative of the severity of said nucleolar
disruption, or the severity or grade of said health status;
optionally wherein said health status or diagnosis is indicative of cancer, autoimmune disease,
viral infection, neurodegenerative disorder, or ribosomopathy (such as cancer predisposition, skeletal
problems, or hematological problems).
21. A method for quantifying nucleolar integrity or nucleolar disruption, comprising the steps of:
a) identifying one or more nucleolar morphometric characteristic capable of discriminating
between different nucleolar morphologies or architectures, preferably capable of discriminating
between normal and disrupted nucleolar morphology, architecture, or integrity, preferably according
to Fisher' s criterium;
b) assigning a numerical value to each of said one or more morphometric characteristic, wherein
said value correlates with the distance between said morphometric characteristic of said normal and
disrupted nucleolar morphologies or architectures; and
c) integrating all numerical values to obtain a global score which quantifies nucleolar integrity or
nucleolar disruption.
22. A method for identifying a set of one or more nucleolar morphometric characteristics that
discriminate between two cells or cell populations, comprising the steps of:
a) defining a set of arbitrary parametric morphometric characteristics to capture the most
salient morphometric differences observed between representative nucleoli samples of two populations of
interest;
b) selecting the parameters associated to each morphometric characteristic to maximize their
discriminating power and/or to minimize the overlap between the morphometric characteristic
probabilistic distributions derived from each population, preferably according to Fisher's criterium; and
c) selecting the morphometric characteristics and their associated optimized parameters leading to
a large separation between populations to discriminate;
d) computing the distance between the two cells or cell populations based on a combination, e.g.
using a weighted summation, of the distances measured in terms of the selected morphometric
characteristics.
23. Use of a method according to any of claims 1,2 or 4 to 20 for identifying compounds affecting
nucleolar morphology, architecture, integrity, or disruption or for identifying compounds affecting p53
stability and/or steady state levels.





































